BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509-8521. [PMID: 30520029 DOI: 10.1002/jcp.27782] [Cited by in Crossref: 258] [Cited by in F6Publishing: 461] [Article Influence: 64.5] [Reference Citation Analysis]
Number Citing Articles
1 Shen Y, Nussbaum YI, Manjunath Y, Hummel JJ, Ciorba MA, Warren WC, Kaifi JT, Papageorgiou C, Cortese R, Shyu C, Mitchem JB. TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer. Cancers 2022;14:4594. [DOI: 10.3390/cancers14194594] [Reference Citation Analysis]
2 Liao N, Li C, Cao L, Chen Y, Ren C, Chen X, Mok H, Wen L, Li K, Wang Y, Zhang Y, Li Y, Lv J, Cao F, Luo Y, Li H, Wu W, Balch CM, Giuliano AE. Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. Breast Cancer 2022. [PMID: 36129636 DOI: 10.1007/s12282-022-01400-x] [Reference Citation Analysis]
3 Liu M, Hu W, Zhang Y, Zhang N, Chen L, Lin Y, Wang Y, Luo Y, Guo Y, Chen M, Chen J. Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. Front Oncol 2022;12:917743. [DOI: 10.3389/fonc.2022.917743] [Reference Citation Analysis]
4 Zhou X, Ni Y, Liang X, Lin Y, An B, He X, Zhao X. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol 2022;13:915094. [DOI: 10.3389/fimmu.2022.915094] [Reference Citation Analysis]
5 Kousar K, Ahmad T, Naseer F, Kakar S, Anjum S. Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma. Cancers 2022;14:4458. [DOI: 10.3390/cancers14184458] [Reference Citation Analysis]
6 Fameli A, Nardone V, Shekarkar Azgomi M, Bianco G, Gandolfo C, Oliva BM, Monoriti M, Saladino RE, Falzea A, Romeo C, Calandruccio ND, Azzarello D, Giannicola R, Pirtoli L, Giordano A, Tassone P, Tagliaferri P, Cusi MG, Mutti L, Botta C, Correale P. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach. Front Oncol 2022;12:911579. [DOI: 10.3389/fonc.2022.911579] [Reference Citation Analysis]
7 Charbel A, Tavernar L, Albrecht T, Brinkmann F, Verheij J, Roos E, Vogel MN, Köhler B, Springfeld C, Brobeil A, Schirmacher P, Singer S, Mehrabi A, Roessler S, Goeppert B. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. Br J Cancer 2022. [PMID: 36068277 DOI: 10.1038/s41416-022-01933-0] [Reference Citation Analysis]
8 Wolf EM, Fingleton B, Hasty AH. The therapeutic potential of TREM2 in cancer. Front Oncol 2022;12:984193. [DOI: 10.3389/fonc.2022.984193] [Reference Citation Analysis]
9 Zheng Y, Wang P, Fu Y, Chen Y, Ding Z. Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. International Immunopharmacology 2022;110:109030. [DOI: 10.1016/j.intimp.2022.109030] [Reference Citation Analysis]
10 Takahashi R, Ijichi H, Fujishiro M. The Role of Neural Signaling in the Pancreatic Cancer Microenvironment. Cancers 2022;14:4269. [DOI: 10.3390/cancers14174269] [Reference Citation Analysis]
11 Burandt E, Blessin NC, Rolschewski A, Lutz F, Mandelkow T, Yang C, Bady E, Reiswich V, Simon R, Sauter G, Mahner S, Gregorio ND, Klapdor R, Kalder M, Braicu EI, Fürst S, Klar M, Strauß H, Prieske K, Wölber L. T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. Cancers 2022;14:4246. [DOI: 10.3390/cancers14174246] [Reference Citation Analysis]
12 Guo K, Duan X, Zhao J, Sun B, Liu X, Zhao Z. A novel necroptosis-related gene signature for predict prognosis of glioma based on single-cell and bulk RNA sequencing. Front Mol Biosci 2022;9:984712. [DOI: 10.3389/fmolb.2022.984712] [Reference Citation Analysis]
13 Luo Z, Liang X, He T, Qin X, Li X, Li Y, Li L, Loh XJ, Gong C, Liu X. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation. J Am Chem Soc 2022. [PMID: 36037283 DOI: 10.1021/jacs.2c03266] [Reference Citation Analysis]
14 Füchsl F, Krackhardt AM. Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers 2022;14:4192. [DOI: 10.3390/cancers14174192] [Reference Citation Analysis]
15 Chen Y, Qiu X, Wu D, Lu X, Li G, Tang Y, Jia C, Xiong Z, Wang T. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes 2022;13:1535. [DOI: 10.3390/genes13091535] [Reference Citation Analysis]
16 Huang X, Wang Y, Yang W, Dong J, Li L. Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. Front Nutr 2022;9:974896. [DOI: 10.3389/fnut.2022.974896] [Reference Citation Analysis]
17 Liu J, Wang Y, Zhao X, Wang K, Wang C, Du J. Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma. Aging (Albany NY) 2022;14. [PMID: 36006412 DOI: 10.18632/aging.204244] [Reference Citation Analysis]
18 Tian Z, Yao W. PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas. Front Immunol 2022;13:898255. [DOI: 10.3389/fimmu.2022.898255] [Reference Citation Analysis]
19 Yin T, Yin Y, Qu L. Exploration of shared gene signature with development of pre-eclampsia and cervical cancer. Front Genet 2022;13:972346. [DOI: 10.3389/fgene.2022.972346] [Reference Citation Analysis]
20 Cao S, Hung YW, Wang YC, Chung Y, Qi Y, Ouyang C, Zhong X, Hu W, Coblentz A, Maghami E, Sun Z, Lin HH, Ann DK. Glutamine is essential for overcoming the immunosuppressive microenvironment in malignant salivary gland tumors. Theranostics 2022;12:6038-56. [PMID: 35966597 DOI: 10.7150/thno.73896] [Reference Citation Analysis]
21 Wei W, Zhang Y. PSEN1 is associated with colon cancer development via potential influences on PD-L1 nuclear translocation and tumor-immune interactions. Front Immunol 2022;13:927474. [DOI: 10.3389/fimmu.2022.927474] [Reference Citation Analysis]
22 Zhang X, Yang Q, Ashfaq UA. An Immune-Related lncRNA Pairing Model for Predicting the Prognosis and Immune-Infiltrating Cell Condition in Human Ovarian Cancer. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/3168408] [Reference Citation Analysis]
23 Zhu Y, Li X, Wang L, Hong X, Yang J. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. Front Endocrinol 2022;13:988295. [DOI: 10.3389/fendo.2022.988295] [Reference Citation Analysis]
24 Liu J, Li W, Wu L. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma. Front Pharmacol 2022;13:950156. [DOI: 10.3389/fphar.2022.950156] [Reference Citation Analysis]
25 Niu D, Chen Y, Mi H, Mo Z, Pang G. The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Front Genet 2022;13:974416. [DOI: 10.3389/fgene.2022.974416] [Reference Citation Analysis]
26 Tan R, Nie M, Long W. The role of B cells in cancer development. Front Oncol 2022;12:958756. [DOI: 10.3389/fonc.2022.958756] [Reference Citation Analysis]
27 Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol 2022;13:963533. [DOI: 10.3389/fimmu.2022.963533] [Reference Citation Analysis]
28 Shefer A, Yalovaya A, Tamkovich S. Exosomes in Breast Cancer: Involvement in Tumor Dissemination and Prospects for Liquid Biopsy. IJMS 2022;23:8845. [DOI: 10.3390/ijms23168845] [Reference Citation Analysis]
29 Shan M, Liu H, Hao Y, Song K, Feng C, Wang Y. The Role of CD28 and CD8+ T Cells in Keloid Development. IJMS 2022;23:8862. [DOI: 10.3390/ijms23168862] [Reference Citation Analysis]
30 Wang L, Yuan W, Li L, Shen Z, Geng Q, Zheng Y, Zhao J, Behzadi P. Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma. Journal of Immunology Research 2022;2022:1-16. [DOI: 10.1155/2022/9544827] [Reference Citation Analysis]
31 Bi Y, Meng D, Wan M, Xu N, Xu Y, Yuan K, Liu P, Fang H, Hu H, Lan S, Chen D. m6A-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Osteosarcoma. Computational Intelligence and Neuroscience 2022;2022:1-16. [DOI: 10.1155/2022/9315283] [Reference Citation Analysis]
32 Wu J, Li N, Zhu L, Zhen D, Li M, Chen H, Ye M, Wei Y, Shao G. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis. BMC Bioinformatics 2022;23:312. [PMID: 35918642 DOI: 10.1186/s12859-022-04862-0] [Reference Citation Analysis]
33 Chen Y, Yuan X, Pei C, Deng Z, Du X, Liang J, He L, Hou S. Vitexin alleviates breast tumor in mice via skewing TAMs toward an iNOS+ profile orchestrating effective CD8+ T cell activation. Journal of Functional Foods 2022;95:105190. [DOI: 10.1016/j.jff.2022.105190] [Reference Citation Analysis]
34 Nkanga CI, Ortega-Rivera OA, Steinmetz NF. Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosaic virus with polydopamine coat. Nanomedicine 2022;44:102573. [PMID: 35728739 DOI: 10.1016/j.nano.2022.102573] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Deng J, Jiang R, Meng E, Wu H. CXCL5: A coachman to drive cancer progression. Front Oncol 2022;12:944494. [DOI: 10.3389/fonc.2022.944494] [Reference Citation Analysis]
36 Ye X, Liu X, Yin N, Song W, Lu J, Yang Y, Chen X. Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report. Front Immunol 2022;13:956519. [DOI: 10.3389/fimmu.2022.956519] [Reference Citation Analysis]
37 Tong L, Shan M, Zou W, Liu X, Felsher DW, Wang J. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells. Front Oncol 2022;12:904969. [DOI: 10.3389/fonc.2022.904969] [Reference Citation Analysis]
38 Wei J, Yao J, Yan M, Xie Y, Liu P, Mao Y, Li X. The role of matrix stiffness in cancer stromal cell fate and targeting therapeutic strategies. Acta Biomaterialia 2022. [DOI: 10.1016/j.actbio.2022.08.005] [Reference Citation Analysis]
39 Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y, Gao H, Wang Q, Wang Y. Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. Cancer Cell Int 2022;22:242. [PMID: 35906622 DOI: 10.1186/s12935-022-02664-1] [Reference Citation Analysis]
40 Song H, Sun H, He N, Xu C, Wang Y, Du L, Liu Y, Wang Q, Ji K, Wang J, Zhang M, Gu Y, Zhang Y, Feng L, Tillement O, Wang W, Liu Q. Gadolinium-based ultra-small nanoparticles augment radiotherapy-induced T-cell response to synergize with checkpoint blockade immunotherapy. Nanoscale 2022. [PMID: 35904053 DOI: 10.1039/d2nr02620a] [Reference Citation Analysis]
41 Li Z, Wang J, Chen C, He Q, Xu X, Da Z, Wang B, Wang M, Gao X, Zhang G, Gao Q, Si X, Luo Y, Ma X, Xu B. Intratumoral IL-28B Gene Delivery Elicits Antitumor Effects by Remodeling of the Tumor Microenvironment in H22-Bearing Mice. Journal of Immunology Research 2022;2022:1-13. [DOI: 10.1155/2022/1345971] [Reference Citation Analysis]
42 Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C. Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol 2022;13:844142. [PMID: 35874717 DOI: 10.3389/fimmu.2022.844142] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Chun J, Park SM, Yi JM, Ha IJ, Kang HN, Jeong MK. Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice. Front Pharmacol 2022;13:901563. [PMID: 35873573 DOI: 10.3389/fphar.2022.901563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Zhang T, Yu H, Dai X, Zhang X. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Front Immunol 2022;13:971428. [DOI: 10.3389/fimmu.2022.971428] [Reference Citation Analysis]
45 Escriche-Navarro B, Escudero A, Lucena-Sánchez E, Sancenón F, García-Fernández A, Martínez-Máñez R. Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. Adv Sci (Weinh) 2022;:e2200756. [PMID: 35866466 DOI: 10.1002/advs.202200756] [Reference Citation Analysis]
46 Perri F, Della Vittoria Scarpati G, Pontone M, Marciano ML, Ottaiano A, Cascella M, Sabbatino F, Guida A, Santorsola M, Maiolino P, Cavalcanti E, Togo G, Ionna F, Caponigro F. Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A Review. Cancers 2022;14:3560. [DOI: 10.3390/cancers14153560] [Reference Citation Analysis]
47 Ni L, Huang J, Ding J, Kou J, Shao T, Li J, Gao L, Zheng W, Wu Z. Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Nutr 2022;9:823087. [DOI: 10.3389/fnut.2022.823087] [Reference Citation Analysis]
48 Sumitani N, Ishida K, Sawada K, Kimura T, Kaneda Y, Nimura K. Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing. Cancers 2022;14:3580. [DOI: 10.3390/cancers14153580] [Reference Citation Analysis]
49 Zhang S, Zhang W, Zhang J. 8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. Front Genet 2022;13:938611. [DOI: 10.3389/fgene.2022.938611] [Reference Citation Analysis]
50 Xu JL. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer. Dig Dis Sci 2022. [PMID: 35859262 DOI: 10.1007/s10620-022-07620-7] [Reference Citation Analysis]
51 Chong YP, Peter EP, Lee FJM, Chan CM, Chai S, Ling LPC, Tan EL, Ng SH, Masamune A, Ghafar SAA, Ismail N, Ho KL. Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression. Sci Rep 2022;12:12315. [PMID: 35853996 DOI: 10.1038/s41598-022-16671-9] [Reference Citation Analysis]
52 Li B, Wang B. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression. Immunological Investigations. [DOI: 10.1080/08820139.2022.2083972] [Reference Citation Analysis]
53 Jia J, Ga L, Liu Y, Yang Z, Wang Y, Guo X, Ma R, Liu R, Li T, Tang Z, Wang J. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Front Immunol 2022;13:923031. [DOI: 10.3389/fimmu.2022.923031] [Reference Citation Analysis]
54 Li W, Wu F, Zhao S, Shi P, Wang S, Cui D. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine Growth Factor Rev 2022:S1359-6101(22)00054-5. [PMID: 35871139 DOI: 10.1016/j.cytogfr.2022.07.004] [Reference Citation Analysis]
55 Hou J, Huang Q, Fan Z, Sang H, Wu S, Cheng S, Li Q, Tang M. LncRNA OIP5-AS1 Knockdown Facilitated the Ferroptosis and Immune Evasion by Modulating the GPX4 in Oesophageal Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-14. [DOI: 10.1155/2022/8103198] [Reference Citation Analysis]
56 Jin Y, Wang Z, Tang W, Liao M, Wu X, Wang H. An Integrated Analysis of Prognostic Signature and Immune Microenvironment in Tongue Squamous Cell Carcinoma. Front Oncol 2022;12:891716. [DOI: 10.3389/fonc.2022.891716] [Reference Citation Analysis]
57 Chen Y, Zhou M, Gu X, Wang L, Wang C, Sun Y. High Expression of TACC3 Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients. Disease Markers 2022;2022:1-22. [DOI: 10.1155/2022/8789515] [Reference Citation Analysis]
58 Bonnereau J, Courau T, Asesio N, Salfati D, Bouhidel F, Corte H, Hamoudi S, Hammoudi N, Lavolé J, Vivier-Chicoteau J, Chardiny V, Maggiori L, Blery M, Remark R, Bonnafous C, Cattan P, Toubert A, Bhat P, Allez M, Aparicio T, Le Bourhis L. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. Gut 2022:gutjnl-2021-326553. [PMID: 35803702 DOI: 10.1136/gutjnl-2021-326553] [Reference Citation Analysis]
59 Wang G, Yang L, Wang Y, Hu R, Zhang K, Guo T, Chen B, Jiang X, Cui R. Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer. Front Immunol 2022;13:939836. [DOI: 10.3389/fimmu.2022.939836] [Reference Citation Analysis]
60 Liu X, Jiang Y, Sun X, Zhao J, Zhang L, Jing X. Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2022;12:938549. [DOI: 10.3389/fonc.2022.938549] [Reference Citation Analysis]
61 Shui IM, Liu XQ, Zhao Q, Kim ST, Sun Y, Yearley JH, Choudhury T, Webber AL, Krepler C, Cristescu R, Lee J. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. J Immunother Cancer 2022;10:e004879. [PMID: 35793874 DOI: 10.1136/jitc-2022-004879] [Reference Citation Analysis]
62 Alruwaii ZI, Montgomery EA. Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. Adv Anat Pathol 2022;29:183-93. [PMID: 35470287 DOI: 10.1097/PAP.0000000000000346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wang X, Shi Z, Luo J, Zeng Y, He L, Chen L, Yao J, Zhang T, Huang P. Ultrasound improved immune adjuvant delivery to induce DC maturation and T cell activation. J Control Release 2022:S0168-3659(22)00396-0. [PMID: 35780954 DOI: 10.1016/j.jconrel.2022.06.054] [Reference Citation Analysis]
64 Jiang Y, Luo K, Xu J, Shen X, Gao Y, Fu W, Zhang X, Wang H, Liu B. Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network. Front Oncol 2022;12:912537. [DOI: 10.3389/fonc.2022.912537] [Reference Citation Analysis]
65 Feng Z, Chen Y, Cai C, Tan J, Liu P, Chen Y, Shen H, Zeng S, Han Y. Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker. Front Immunol 2022;13:916594. [DOI: 10.3389/fimmu.2022.916594] [Reference Citation Analysis]
66 Sun D, Gai Z, Wu J, Chen Q. Prognostic Impact of the Angiogenic Gene POSTN and Its Related Genes on Lung Adenocarcinoma. Front Oncol 2022;12:699824. [DOI: 10.3389/fonc.2022.699824] [Reference Citation Analysis]
67 Choi J, Sarker A, Choi H, Lee DS, Im HJ. Prognostic impact of an integrative analysis of [18F]FDG PET parameters and infiltrating immune cell scores in lung adenocarcinoma. EJNMMI Res 2022;12:38. [PMID: 35759068 DOI: 10.1186/s13550-022-00908-9] [Reference Citation Analysis]
68 Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res 2022. [PMID: 35759090 DOI: 10.1007/s12272-022-01389-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Hao X, Liu X, Yu S, Qin C, Wang R, Li C, Shao J. Intravenous As2O3 as a promising treatment for psoriasis - an experimental study in psoriasis-like mouse model. Immunopharmacol Immunotoxicol 2022;:1-46. [PMID: 35748353 DOI: 10.1080/08923973.2022.2093742] [Reference Citation Analysis]
70 Wang Y, Rousset X, Prunier C, Garcia P, Dosda E, Leplus E, Viallet J. PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo. Cancers 2022;14:3095. [DOI: 10.3390/cancers14133095] [Reference Citation Analysis]
71 Deng Z, Tian Y, Song J, An G, Yang P. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Front Immunol 2022;13:887125. [PMID: 35720301 DOI: 10.3389/fimmu.2022.887125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 XiaYu K, GuoGang C, CanXuan L, WeiBin X. Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction. Dis Markers 2022;2022:2360299. [PMID: 35711565 DOI: 10.1155/2022/2360299] [Reference Citation Analysis]
73 Li X, Zhou X, Liu J, Zhang J, Feng Y, Wang F, He Y, Wan A, Filipczak N, Yalamarty SSK, Jin Y, Torchilin VP. Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect. ACS Appl Mater Interfaces 2022. [PMID: 35726706 DOI: 10.1021/acsami.2c01123] [Reference Citation Analysis]
74 Islam SI, Mahfuj S, Islam MJ, Mou MJ, Sanjida S. Use of Integrated Core Proteomics, Immuno-Informatics, and In Silico Approaches to Design a Multiepitope Vaccine against Zoonotic Pathogen Edwardsiella tarda. Applied Microbiology 2022;2:414-37. [DOI: 10.3390/applmicrobiol2020031] [Reference Citation Analysis]
75 Zhang J, Wang L, Li S, Gao X, Liu Z. CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy. Cancer Cell Int 2022;22:216. [PMID: 35715855 DOI: 10.1186/s12935-022-02630-x] [Reference Citation Analysis]
76 Cao W, Lu J, Li L, Qiu C, Qin X, Wang T, Li S, Zhang J, Xu J. Activation of the Aryl Hydrocarbon Receptor Ameliorates Acute Rejection of Rat Liver Transplantation by Regulating Treg Proliferation and PD-1 Expression. Transplantation 2022. [PMID: 35706097 DOI: 10.1097/TP.0000000000004205] [Reference Citation Analysis]
77 Pang R, Qin C. Development of a Risk Predictive Model for Evaluating Immune Infiltration Status in Invasive Thyroid Carcinoma. Evid Based Complement Alternat Med 2022;2022:5803077. [PMID: 35692574 DOI: 10.1155/2022/5803077] [Reference Citation Analysis]
78 Wang J, Zhou CC, Sun HC, Li Q, Hu JD, Jiang T, Zhou S. Identification of several senescence-associated genes signature in head and neck squamous cell carcinoma. J Clin Lab Anal 2022;:e24555. [PMID: 35692082 DOI: 10.1002/jcla.24555] [Reference Citation Analysis]
79 Jiang W, Xie N, Xu C. Characterization of a prognostic model for lung squamous cell carcinoma based on eight stemness index-related genes. BMC Pulm Med 2022;22:224. [PMID: 35676660 DOI: 10.1186/s12890-022-02011-0] [Reference Citation Analysis]
80 Li L, Zhao C, Kong F, Li YC, Wang C, Chen S, Tan HY, Liu Y, Wang D. Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function. Front Pharmacol 2022;13:898906. [PMID: 35662701 DOI: 10.3389/fphar.2022.898906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Zhang J, Wang D, Chen X, Ji L, Yu M, Guo M, Zhang D, Chen W, Xu F. Upregulation of Ferroptosis-Related Fanconi Anemia Group D2 is a Poor Prognostic Factor and an Indicator of Tumor Immune Cell Infiltration in Lung Adenocarcinoma. Front Genet 2022;13:825685. [PMID: 35646059 DOI: 10.3389/fgene.2022.825685] [Reference Citation Analysis]
82 Li Y, Zhou J, Chen Y, Pei Q, Li Y, Wang L, Xie Z. Near-Infrared Light-Boosted Photodynamic-Immunotherapy based on sulfonated Metal-Organic framework nanospindle. Chemical Engineering Journal 2022;437:135370. [DOI: 10.1016/j.cej.2022.135370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wang J, Liu Y, Ni W, Wu X, Zhou J, Zhang Z, Zhou H, Zhang N, Jiang M, Sang Q, Yuan H, Tai G. TRAF6-overexpressing dendritic cells loaded with MUC1 peptide enhance anti-tumor activity in B16-MUC1 melanoma-bearing mice. International Immunopharmacology 2022;107:108667. [DOI: 10.1016/j.intimp.2022.108667] [Reference Citation Analysis]
84 Zhang Q, Li S, Ren J, He X, Shi H, Zhang F, Li H, Tong R. ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma. J Control Release 2022;348:22-33. [PMID: 35461966 DOI: 10.1016/j.jconrel.2022.04.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Yoneta D, Kato J, Kamiya T, Horimoto K, Sato S, Sawada M, Minowa T, Hida T, Sugita S, Uhara H. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients. Int J Clin Oncol 2022. [PMID: 35650364 DOI: 10.1007/s10147-022-02189-7] [Reference Citation Analysis]
86 Zhao J, Huang H, Zhao J, Xiong X, Zheng S, Wei X, Zhou S. A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy. Acta Pharmaceutica Sinica B 2022;12:2683-94. [DOI: 10.1016/j.apsb.2021.10.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Zhang Q, Liu YJ, Li JP, Zeng SH, Shen H, Han M, Guo S, Liu SL, Zou X. USP35 is a Potential Immunosuppressive Factor in Skin Cutaneous Melanoma. J Inflamm Res 2022;15:3065-82. [PMID: 35637872 DOI: 10.2147/JIR.S362619] [Reference Citation Analysis]
88 Zhou K, Hu N, Hong Y, Wu X, Zhang J, Lai H, Zhang Y, Wu F. An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas. Front Genet 2022;13:903393. [DOI: 10.3389/fgene.2022.903393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mohammad Mirzaei N, Tatarova Z, Hao W, Changizi N, Asadpoure A, Zervantonakis IK, Hu Y, Chang YH, Shahriyari L. A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice. JPM 2022;12:807. [DOI: 10.3390/jpm12050807] [Reference Citation Analysis]
90 Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder. BMC Cancer 2022;22:556. [PMID: 35581573 DOI: 10.1186/s12885-022-09606-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Liu K, Huang J, Liu J, Li C, Kroemer G, Tang D, Kang R. HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy. Cancer Res 2022;82:2003-18. [PMID: 35247909 DOI: 10.1158/0008-5472.CAN-21-3917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Sim W, Lim WM, Hii LW, Leong CO, Mai CW. Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. World J Gastroenterol 2022; 28(18): 1934-1945 [DOI: 10.3748/wjg.v28.i18.1934] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Tian XM, Xiang B, Zhang ZX, Li YP, Shi QL, Li MJ, Li Q, Yu YH, Lu P, Liu F, Liu X, Lin T, He DW, Wei GH. The Regulatory Network and Role of the circRNA-miRNA-mRNA ceRNA Network in the Progression and the Immune Response of Wilms Tumor Based on RNA-Seq. Front Genet 2022;13:849941. [PMID: 35559038 DOI: 10.3389/fgene.2022.849941] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Xu F, Guan Y, Zhang P, Xue L, Ma Y, Gao M, Chong T, Ren BC. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma. BMC Endocr Disord 2022;22:130. [PMID: 35568842 DOI: 10.1186/s12902-022-01017-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Zhang X, He Q, Sun J, Gong H, Cao Y, Duan L, Yi S, Ying B, Xiao B. Near-Infrared-Enpowered Nanomotor-Mediated Targeted Chemotherapy and Mitochondrial Phototherapy to Boost Systematic Antitumor Immunity. Adv Healthc Mater 2022;:e2200255. [PMID: 35536883 DOI: 10.1002/adhm.202200255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Su Y, Xu B, Shen Q, Lei Z, Zhang W, Hu T. LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma. Front Immunol 2022;13:788375. [PMID: 35273591 DOI: 10.3389/fimmu.2022.788375] [Reference Citation Analysis]
97 Zhang M, Ma J, Guo Q, Ding S, Wang Y, Pu H. CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma. Front Immunol 2022;13:806877. [PMID: 35273597 DOI: 10.3389/fimmu.2022.806877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
98 Towlerton AMH, Ravishankar S, Coffey DG, Puronen CE, Warren EH. Serial Analysis of the T-Cell Receptor β-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy. Front Immunol 2022;13:879190. [DOI: 10.3389/fimmu.2022.879190] [Reference Citation Analysis]
99 Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Cao J, Huang G, Zhang J, Sumer B, Lea J, Lu Z, Gao J, Luo M. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer 2022;10:e003960. [PMID: 35623658 DOI: 10.1136/jitc-2021-003960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev 2022;36:582-600. [PMID: 35654454 DOI: 10.1101/gad.349321.121] [Reference Citation Analysis]
101 Song L, Liu S, Zhao S. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. Bioengineered 2022;13:11240-57. [PMID: 35485300 DOI: 10.1080/21655979.2022.2064205] [Reference Citation Analysis]
102 Zhang G, Luo Y, Dong W, Zhong W, Ding H. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. Computational and Mathematical Methods in Medicine 2022;2022:1-51. [DOI: 10.1155/2022/8233840] [Reference Citation Analysis]
103 Hua W, Huang X, Li J, Feng W, Sun Y, Guo C. 2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity. Immunopharmacol Immunotoxicol 2022;:1-7. [PMID: 35451929 DOI: 10.1080/08923973.2022.2062380] [Reference Citation Analysis]
104 Wang R, Guo Y, Ma P, Song Y, Min J, Zhao T, Hua L, Zhang C, Yang C, Shi J, Zhu L, Gan D, Li S, Li J, Su H. Comprehensive Analysis of 5-Methylcytosine (m5C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy. Front Oncol 2022;12:851766. [PMID: 35433474 DOI: 10.3389/fonc.2022.851766] [Reference Citation Analysis]
105 Yan H, Shi J, Dai Y, Li X, Wu Y, Zhang J, Gu Z, Zhang C, Leng J. Technique integration of single-cell RNA sequencing with spatially resolved transcriptomics in the tumor microenvironment. Cancer Cell Int 2022;22:155. [PMID: 35440049 DOI: 10.1186/s12935-022-02580-4] [Reference Citation Analysis]
106 Zeng X, Li L, Hu Z, Peng D. Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Front Oncol 2022;12:832027. [PMID: 35433461 DOI: 10.3389/fonc.2022.832027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Zhu L, Zhu X, Wu Y. Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications. Biomolecules 2022;12:580. [DOI: 10.3390/biom12040580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
108 Knörck A, Schäfer G, Alansary D, Richter J, Thurner L, Hoth M, Schwarz EC. Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes. Front Immunol 2022;13:838484. [DOI: 10.3389/fimmu.2022.838484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Badiee P, Maritz MF, Dmochowska N, Cheah E, Thierry B. Intratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution. ACS Appl Mater Interfaces 2022;14:15881-93. [PMID: 35357803 DOI: 10.1021/acsami.1c22479] [Reference Citation Analysis]
110 Islam SI, Mou MJ, Sanjida S, Tariq M, Nasir S, Mahfuj S. Designing a novel mRNA vaccine against Vibrio harveyi infection in fish: an immunoinformatics approach. Genomics Inform 2022;20:e11. [PMID: 35399010 DOI: 10.5808/gi.21065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Wang Y, Yang Y, Zhao Z, Sun H, Luo D, Huttad L, Zhang B, Han B. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09465-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Zhao Y, Song Q, Xu F, Zhou Y, Zuo X, Zhang Z. Pyroptosis-Related Risk Signature Exhibits Distinct Prognostic, Immune, and Therapeutic Landscapes in Hepatocellular Carcinoma. Front Genet 2022;13:823443. [PMID: 35368686 DOI: 10.3389/fgene.2022.823443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, Shu X, He Y, Xiao W, Tian Z. Advances in NK cell production. Cell Mol Immunol 2022;19:460-81. [PMID: 34983953 DOI: 10.1038/s41423-021-00808-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Costa VR, Soileau AM, Liu C, Moeller CE, Carossino M, Langohr IM, Withers SS. Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors. Research in Veterinary Science 2022. [DOI: 10.1016/j.rvsc.2022.04.005] [Reference Citation Analysis]
115 Dong X, Akuetteh PDP, Song J, Ni C, Jin C, Li H, Jiang W, Si Y, Zhang X, Zhang Q, Huang G. Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways. Front Cell Dev Biol 2022;9:688370. [DOI: 10.3389/fcell.2021.688370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J, Zhang X, Zhu W. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:813275. [DOI: 10.3389/fonc.2022.813275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Zhong B, Zheng J, Wen H, Liao X, Chen X, Rao Y, Yuan P. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells. Genes Genomics 2022. [PMID: 35353342 DOI: 10.1007/s13258-022-01238-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Haruna M, Ueyama A, Yamamoto Y, Hirata M, Goto K, Yoshida H, Higuchi N, Yoshida T, Kidani Y, Nakamura Y, Nagira M, Kawashima A, Iwahori K, Shintani Y, Ohkura N, Wada H. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-09458-5] [Reference Citation Analysis]
119 Zhu Y, Fu D, Shi Q, Shi Z, Dong L, Yi H, Liu Z, Feng Y, Liu Q, Fang H, Cheng S, Wang L, Tian Q, Xu P, Zhao W. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. Front Immunol 2022;13:842439. [DOI: 10.3389/fimmu.2022.842439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Wang Z, Zhang H, Zhai Y, Li F, Shi X, Ying M. Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma. Front Immunol 2022;13:843322. [DOI: 10.3389/fimmu.2022.843322] [Reference Citation Analysis]
121 Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J Immunother Cancer 2022;10:e004306. [PMID: 35314434 DOI: 10.1136/jitc-2021-004306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
122 Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer 2022;10:e003883. [PMID: 35314433 DOI: 10.1136/jitc-2021-003883] [Reference Citation Analysis]
123 Worlikar T, Zhang M, Ganguly A, Hall TL, Shi J, Zhao L, Lee FT, Mendiratta-Lala M, Cho CS, Xu Z. Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model. Cancers (Basel) 2022;14:1612. [PMID: 35406383 DOI: 10.3390/cancers14071612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Xue T, Zhang Z, Fang T, Li B, Li Y, Li L, Jiang Y, Duan F, Meng F, Liang X, Zhang X. Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer. Nano Res . [DOI: 10.1007/s12274-022-4182-0] [Reference Citation Analysis]
125 Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol 2022;15:28. [PMID: 35303904 DOI: 10.1186/s13045-022-01247-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
126 Hussain MWA, Jahangir S, Ghosh B, Yesmin F, Anis A, Satil SN, Anwar F, Rashid MH. Exosomes for Regulation of Immune Responses and Immunotherapy. JNT 2022;3:55-85. [DOI: 10.3390/jnt3010005] [Reference Citation Analysis]
127 García-domínguez DJ, Hontecillas-prieto L, Palazón-carrión N, Jiménez-cortegana C, Sánchez-margalet V, de la Cruz-merino L. Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers 2022;14:1469. [DOI: 10.3390/cancers14061469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Chiang I, Lee Y, Tan Z, Hsu F, Tu H. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomedicine & Pharmacotherapy 2022;147:112661. [DOI: 10.1016/j.biopha.2022.112661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
129 Haegebaert RM, Kempers M, Ceelen W, Lentacker I, Remaut K. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics 2022;172:16-30. [DOI: 10.1016/j.ejpb.2022.01.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Li J, Luo G, Zhang C, Long S, Guo L, Yang G, Wang F, Zhang L, Shi L, Fu Y, Zhang Y. In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy. Materials Today Bio 2022;14:100238. [DOI: 10.1016/j.mtbio.2022.100238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Goggi JL, Khanapur S, Ramasamy B, Hartimath SV, Rong TJ, Cheng P, Tan YX, Yeo XY, Jung S, Goay SSM, Ong ST, Hwang YY, Chandy KG, Robins EG. Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response. Cancers 2022;14:1217. [DOI: 10.3390/cancers14051217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
132 Yan J, Ye G, Shao Y. High expression of the ferroptosis-associated MGST1 gene in relation to poor outcome and maladjusted immune cell infiltration in uterine corpus endometrial carcinoma. J Clin Lab Anal 2022;:e24317. [PMID: 35218676 DOI: 10.1002/jcla.24317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Zhuo Z, Lin H, Liang J, Ma P, Li J, Huang L, Chen L, Yang H, Bai Y, Sha W. Mitophagy-Related Gene Signature for Prediction Prognosis, Immune Scenery, Mutation, and Chemotherapy Response in Pancreatic Cancer. Front Cell Dev Biol 2021;9:802528. [PMID: 35198564 DOI: 10.3389/fcell.2021.802528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Wang H, Zhang R, Li E, Yan R, Ma B, Ma Q. Pan-Cancer Transcriptome and Immune Infiltration Analyses Reveal the Oncogenic Role of Far Upstream Element-Binding Protein 1 (FUBP1). Front Mol Biosci 2022;9:794715. [DOI: 10.3389/fmolb.2022.794715] [Reference Citation Analysis]
135 Zhang Y, Zhu S, Du Y, Xu F, Sun W, Xu Z, Wang X, Qian P, Zhang Q, Feng J, Xu Y. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res 2022;41:66. [PMID: 35177112 DOI: 10.1186/s13046-022-02243-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
136 Zhang Y, Wang Y, Li Y, Huang C, Xiao X, Zhong Z, Tang J, Lu H, Tang Y, Yang J. Dihydroartemisinin and Artesunate Inhibit Aerobic Glycolysis via Suppressing c-Myc Signaling in non-small Cell Lung Cancer. Biochem Pharmacol 2022;:114941. [PMID: 35149053 DOI: 10.1016/j.bcp.2022.114941] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Yin M, Hu J, Yuan Z, Luo G, Yao J, Wang R, Liu D, Cao B, Wu W, Hu Z. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway. Cell Cycle 2022;:1-13. [PMID: 35130108 DOI: 10.1080/15384101.2022.2029996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Wang D, Gong G, Fu Y, Zhu L, Yin H, Liu L, Zhu Z, Zhou G, Yan A, Lei G, Chen C, Pang P, Yi X, Kuang Y, Chen BT. CT imaging findings of renal epithelioid lipid-poor angiomyolipoma. Eur Radiol 2022. [PMID: 35124718 DOI: 10.1007/s00330-021-08528-y] [Reference Citation Analysis]
139 Lee H, Park SJ, Hong S, Lim S, Kim S. Deletion of IP6K1 in mice accelerates tumor growth by dysregulating the tumor-immune microenvironment. Animal Cells and Systems. [DOI: 10.1080/19768354.2022.2029560] [Reference Citation Analysis]
140 Mao R, Hussein MS, He Y. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. Expert Rev Mol Med 2022;24:e7. [PMID: 35086597 DOI: 10.1017/erm.2021.32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Ye Z, Liu D, Liu D, Lv Y, Zhang Y, Zhang J, Bao J, Yuan X, Hou J, Li L. Immune Infiltration of CD8+ T Cells in Patients With Diabetic Pancreatic Cancer Reduces the Malignancy of Cancer Tissues: An In Silico Study. Front Endocrinol 2022;12:826667. [DOI: 10.3389/fendo.2021.826667] [Reference Citation Analysis]
142 Fan Y, Dong X, Li M, Liu P, Zheng J, Li H, Zhang Y. LncRNA KRT19P3 Is Involved in Breast Cancer Cell Proliferation, Migration and Invasion. Front Oncol 2021;11:799082. [PMID: 35059320 DOI: 10.3389/fonc.2021.799082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Tong W, Zhu L, Bai Y, Yang L, Liu Z, Zhang Y. Enhancer RNA LINC00242-Induced Expression of PHF10 Drives a Better Prognosis in Pancreatic Adenocarcinoma. Front Oncol 2022;11:795090. [DOI: 10.3389/fonc.2021.795090] [Reference Citation Analysis]
144 Xie J, Cui L, Pan S, Liu D, Liu F, Liu Z, Zhang Y. Metabolic Understanding of the Genetic Dysregulation in the Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/6085072] [Reference Citation Analysis]
145 Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11:320. [DOI: 10.3390/cells11030320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
146 Nyati KK, Kishimoto T. Recent Advances in the Role of Arid5a in Immune Diseases and Cancer. Front Immunol 2022;12:827611. [DOI: 10.3389/fimmu.2021.827611] [Reference Citation Analysis]
147 Li L, Zhang C, Huang C, Tian X, Sun W, Jiang S, Heredia J. Research Advances in Antitumor Mechanism of Evodiamine. Journal of Chemistry 2022;2022:1-12. [DOI: 10.1155/2022/2784257] [Reference Citation Analysis]
148 Samuels M, Cilibrasi C, Papanastasopoulos P, Giamas G. Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. Biomolecules 2022;12:132. [DOI: 10.3390/biom12010132] [Reference Citation Analysis]
149 Zhang M, Qin X, Zhao Z, Du Q, Li Q, Jiang Y, Luan Y. A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy. Nanoscale Horiz 2022. [PMID: 35023537 DOI: 10.1039/d1nh00506e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
150 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
151 Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 2022. [PMID: 35013615 DOI: 10.1038/s41591-021-01600-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
152 Wu T, Zhang L, Zeng Z, Yan T, Cheng J, Miao X, Lu Y. Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases. Onco Targets Ther 2021;14:5447-53. [PMID: 34984004 DOI: 10.2147/OTT.S333604] [Reference Citation Analysis]
153 Ren S, Wang X, Jin G. Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity. Int J Biol Sci 2022;18:166-79. [PMID: 34975325 DOI: 10.7150/ijbs.64094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Li S, Zhuang S, Heit A, Koo S, Tan AC, Chow I, Kwok WW, Tan IB, Tan DS, Simoni Y, Newell EW. Bystander CD4 + T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology 2022;11:2012961. [DOI: 10.1080/2162402x.2021.2012961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Kongkaew T, Thaiwong R, Tudsamran S, Sae-jung T, Sengprasert P, Vasuratna A, Suppipat K, Reantragoon R. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones. Journal of Immunological Methods 2022. [DOI: 10.1016/j.jim.2022.113229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Li X, Wu G, Chen C, Zhao Y, Zhu S, Song X, Yin J, Lv T, Song Y. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. Front Immunol 2021;12:760683. [PMID: 34966384 DOI: 10.3389/fimmu.2021.760683] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
157 Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Front Immunol 2021;12:768115. [PMID: 34966389 DOI: 10.3389/fimmu.2021.768115] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
158 Klavdianou K, Melissaropoulos K, Filippopoulou A, Daoussis D. Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases. Mediterr J Rheumatol 2021;32:218-26. [PMID: 34964025 DOI: 10.31138/mjr.32.3.218] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
159 Kulmann-Leal B, Ellwanger JH, Chies JAB. CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population. Front Immunol 2021;12:758358. [PMID: 34956188 DOI: 10.3389/fimmu.2021.758358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Ou L, Zhang A, Cheng Y, Chen Y. The cGAS-STING Pathway: A Promising Immunotherapy Target. Front Immunol 2021;12:795048. [PMID: 34956229 DOI: 10.3389/fimmu.2021.795048] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
161 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
162 Na HY, Park Y, Nam SK, Koh J, Kwak Y, Ahn S, Park DJ, Kim H, Lee KS, Lee HS. Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. J Transl Med 2021;19. [DOI: 10.1186/s12967-021-03203-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Al Saber M, Biswas P, Dey D, Kaium MA, Islam MA, Tripty MIA, Rahman MH, Rahaman TI, Biswas MY, Paul P, Rahman MA, Hasan MN, Kim B. A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. Processes 2022;10:16. [DOI: 10.3390/pr10010016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Barbosa CRR, Barton J, Shepherd AJ, Mishto M. Mechanistic diversity in MHC class I antigen recognition. Biochem J 2021;478:4187-202. [PMID: 34940832 DOI: 10.1042/BCJ20200910] [Reference Citation Analysis]
165 Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B, Gao S. Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians. Clin Epigenetics 2021;13:229. [PMID: 34933667 DOI: 10.1186/s13148-021-01221-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Dong Y, Lin X, Kapoor A, Gu Y, Xu H, Major P, Tang D. Insights of RKIP-Derived Suppression of Prostate Cancer. Cancers (Basel) 2021;13:6388. [PMID: 34945007 DOI: 10.3390/cancers13246388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Huang X, Cao J, Zu X. Tumor-associated macrophages: An important player in breast cancer progression. Thorac Cancer 2021. [PMID: 34914196 DOI: 10.1111/1759-7714.14268] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
168 Abu N, Rus Bakarurraini NAA. The interweaving relationship between extracellular vesicles and T cells in cancer. Cancer Lett 2021:S0304-3835(21)00614-5. [PMID: 34906625 DOI: 10.1016/j.canlet.2021.12.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
169 Xu Z, Xiang L, Wang R, Xiong Y, Zhou H, Gu H, Wang J, Peng L. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer. Biomed Res Int 2021;2021:8072796. [PMID: 34888385 DOI: 10.1155/2021/8072796] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
170 Luo Q, Duan Z, Li X, Gu L, Ren L, Zhu H, Tian X, Chen R, Zhang H, Gong Q, Gu Z, Luo K. Branched Polymer‐Based Redox/Enzyme‐Activatable Photodynamic Nanoagent to Trigger STING‐Dependent Immune Responses for Enhanced Therapeutic Effect. Adv Funct Materials 2022;32:2110408. [DOI: 10.1002/adfm.202110408] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
171 Huo J, Cai J, Guan G, Liu H, Wu L. A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:761839. [PMID: 34869350 DOI: 10.3389/fcell.2021.761839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
172 Hua J, Wu P, Gan L, Zhang Z, He J, Zhong L, Zhao Y, Huang Y. Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy. Front Oncol 2021;11:738323. [PMID: 34868932 DOI: 10.3389/fonc.2021.738323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Front Cell Dev Biol 2021;9:775462. [PMID: 34869376 DOI: 10.3389/fcell.2021.775462] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
174 Zhang X, He X, Li Y, Xu Y, Chen W, Liu X, Hu X, Xiong L, Xu X. MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis. Front Mol Biosci 2021;8:702206. [PMID: 34859046 DOI: 10.3389/fmolb.2021.702206] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Guo Y, Wang B, Chen Y, Liang M, Wang H, Wang C, Liang H, Zhou Y, Xi J, Ci L, Sun R, Fei J, Shen R. A bioluminescence reporter mouse strain for in vivo imaging of CD8+ T cell localization and function. Biochem Biophys Res Commun 2021;581:12-9. [PMID: 34653673 DOI: 10.1016/j.bbrc.2021.10.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Lin DL, Wang LL, Zhao P, Ran WW, Wang W, Zhang LX, Han M, Bao H, Liu K, Wu X, Shao Y, Xing XM. Gastrointestinal Goblet Cell Adenocarcinomas Harbor Distinctive Clinicopathological, Immune, and Genomic Landscape. Front Oncol 2021;11:758643. [PMID: 34804955 DOI: 10.3389/fonc.2021.758643] [Reference Citation Analysis]
177 Peng L, Meng C, Li J, You C, Du Y, Xiong W, Xia Z, Cao D, Li Y. The prognostic significance of controlling nutritional status (CONUT) score for surgically treated renal cell cancer and upper urinary tract urothelial cancer: a systematic review and meta-analysis. Eur J Clin Nutr 2021. [PMID: 34815539 DOI: 10.1038/s41430-021-01014-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
178 Gultekin O, Gonzalez-Molina J, Hardell E, Moyano-Galceran L, Mitsios N, Mulder J, Kokaraki G, Isaksson A, Sarhan D, Lehti K, Carlson JW. FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation. NPJ Precis Oncol 2021;5:97. [PMID: 34799669 DOI: 10.1038/s41698-021-00236-6] [Reference Citation Analysis]
179 Gong J, Jin B, Shang L, Liu N. Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy. Front Mol Biosci 2021;8:714053. [PMID: 34790698 DOI: 10.3389/fmolb.2021.714053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Zhou C, Wang S, Shen Z, Shen Y, Li Q, Shen Y, Huang J, Deng H, Ye D, Zhan G, Li J. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma. J Clin Lab Anal 2021;:e24113. [PMID: 34783061 DOI: 10.1002/jcla.24113] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
181 Zhang S, Wan J, Chen M, Cai D, Xu J, Chen Q. Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis. Front Oncol 2021;11:720447. [PMID: 34778035 DOI: 10.3389/fonc.2021.720447] [Reference Citation Analysis]
182 Karmakar S, Pal P, Lal G. Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. Immunotargets Ther 2021;10:387-407. [PMID: 34754837 DOI: 10.2147/ITT.S306109] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
183 Li Q, Yao L, Lin Z, Li F, Xie D, Li C, Zhan W, Lin W, Huang L, Wu S, Zhou H. Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer. Front Oncol 2021;11:706616. [PMID: 34745939 DOI: 10.3389/fonc.2021.706616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Tang L, He S, Yin Y, Liu H, Hu J, Cheng J, Wang W. Combination of Nanomaterials in Cell-Based Drug Delivery Systems for Cancer Treatment. Pharmaceutics 2021;13:1888. [PMID: 34834304 DOI: 10.3390/pharmaceutics13111888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
185 Wei J, Nai GY, Dai Y, Huang XJ, Xiong MY, Yao XY, Huang ZN, Li SN, Zhou WJ, Huang Y, Cheng P, Deng DH. Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia. Ann Transl Med 2021;9:1381. [PMID: 34733933 DOI: 10.21037/atm-21-3368] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
186 Zhang Q, Cheng L, Qin Y, Kong L, Shi X, Hu J, Li L, Ding Z, Wang T, Shen J, Yang Y, Yu L, Liu B, Liu C, Qian X. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers. Clin Transl Immunology 2021;10:e1347. [PMID: 34729183 DOI: 10.1002/cti2.1347] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
187 Peng L, Du C, Meng C, Li J, You C, Li X, Zhao P, Cao D, Li Y. Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods. Front Oncol 2021;11:702908. [PMID: 34722249 DOI: 10.3389/fonc.2021.702908] [Reference Citation Analysis]
188 Xia J, Fan H, Yang J, Song T, Pang L, Deng H, Ren Z, Deng J. Research progress on diarrhoea and its mechanism in weaned piglets fed a high-protein diet. J Anim Physiol Anim Nutr (Berl) 2021. [PMID: 34719816 DOI: 10.1111/jpn.13654] [Reference Citation Analysis]
189 Hashimoto K, Nishimura S, Sakata N, Inoue M, Sawada A, Akagi M. Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis: A retrospective study. Medicine (Baltimore) 2021;100:e27650. [PMID: 34713856 DOI: 10.1097/MD.0000000000027650] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
190 Li X, Yang Y, Huang Q, Deng Y, Guo F, Wang G, Liu M. Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. Front Cell Dev Biol 2021;9:738373. [PMID: 34692696 DOI: 10.3389/fcell.2021.738373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Hu S, Liu H, Zhang J, Li S, Zhou H, Gao Y. Effects and prognostic values of miR-30c-5p target genes in gastric cancer via a comprehensive analysis using bioinformatics. Sci Rep 2021;11:20584. [PMID: 34663825 DOI: 10.1038/s41598-021-00043-w] [Reference Citation Analysis]
192 Capitani N, Patrussi L, Baldari CT. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. Int J Mol Sci 2021;22:11221. [PMID: 34681881 DOI: 10.3390/ijms222011221] [Reference Citation Analysis]
193 Pauli G, Chao PH, Qin Z, Böttger R, Lee SE, Li SD. Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer. Pharmaceutics 2021;13:1696. [PMID: 34683992 DOI: 10.3390/pharmaceutics13101696] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
194 Zhang X, Zhang Y, Zheng H, He Y, Jia H, Zhang L, Lin C, Chen S, Zheng J, Yang Q, Liu T, Pan X, Zhang H, Wang C, Ren L, Shan W. In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy. Acta Biomater 2021;134:633-48. [PMID: 34329780 DOI: 10.1016/j.actbio.2021.07.055] [Reference Citation Analysis]
195 Zeng J, Zhang Y, Shang Y, Mai J, Shi S, Lu M, Bu C, Zhang Z, Zhang Z, Li Y, Du Z, Xiao J. CancerSCEM: a database of single-cell expression map across various human cancers. Nucleic Acids Res 2021:gkab905. [PMID: 34643725 DOI: 10.1093/nar/gkab905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
196 Wan D, Que H, Chen L, Lan T, Hong W, He C, Yang J, Wei Y, Wei X. Lymph-Node-Targeted Cholesterolized TLR7 Agonist Liposomes Provoke a Safe and Durable Antitumor Response. Nano Lett 2021;21:7960-9. [PMID: 34533963 DOI: 10.1021/acs.nanolett.1c01968] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
197 Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021;20:131. [PMID: 34635121 DOI: 10.1186/s12943-021-01428-1] [Cited by in F6Publishing: 79] [Reference Citation Analysis]
198 Wang M, Zhang B. The Immunomodulation Potential of Exosomes in Tumor Microenvironment. J Immunol Res 2021;2021:3710372. [PMID: 34616851 DOI: 10.1155/2021/3710372] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
199 Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel) 2021;13:5004. [PMID: 34638488 DOI: 10.3390/cancers13195004] [Reference Citation Analysis]
200 Gao Y, Ouyang Z, Yang C, Song C, Jiang C, Song S, Shen M, Shi X. Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimer-Based Hybrid Nanocomplex. Adv Healthc Mater 2021;10:e2100833. [PMID: 34212538 DOI: 10.1002/adhm.202100833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
201 Kim CW, Chon HJ, Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers (Basel) 2021;13:4906. [PMID: 34638390 DOI: 10.3390/cancers13194906] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
202 Suzuki K, Nishiwaki K, Yano S. Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. Cancers (Basel) 2021;13:4867. [PMID: 34638353 DOI: 10.3390/cancers13194867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Xiao W, Liang J, Zhang Y, Zhang Y, Teng P, Cao D, Zou S, Xu T, Zhao J, Tang Y. CD8 cell counting in whole blood by a paper-based time-resolved fluorescence lateral flow immunoassay. Anal Chim Acta 2021;1179:338820. [PMID: 34535251 DOI: 10.1016/j.aca.2021.338820] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
204 Ye J, Chen X, Lu W. Identification and Experimental Validation of Immune-Associate lncRNAs for Predicting Prognosis in Cervical Cancer. Onco Targets Ther 2021;14:4721-34. [PMID: 34526775 DOI: 10.2147/OTT.S322998] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
205 Zhu X, Liu J, Pan H, Geng Z, Huang W, Liu T, Zhang B. Thymopentin treatment of murine premature ovarian failure via attenuation of immune cell activity and promotion of the BMP4/Smad9 signalling pathway. Int J Med Sci 2021;18:3544-55. [PMID: 34522181 DOI: 10.7150/ijms.61975] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
206 Lou Y, Wang J, Peng P, Wang S, Liu P, Xu LX. Downregulated TNF-α Levels after Cryo-Thermal Therapy Drive Tregs Fragility to Promote Long-Term Antitumor Immunity. Int J Mol Sci 2021;22:9951. [PMID: 34576115 DOI: 10.3390/ijms22189951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Gong S, Duan Y, Wu C, Osterhoff G, Schopow N, Kallendrusch S. A Human Pan-Cancer System Analysis of Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3). Int J Mol Sci 2021;22:9903. [PMID: 34576068 DOI: 10.3390/ijms22189903] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
208 Gawali VS, Chimote AA, Newton HS, Feria-Garzón MG, Chirra M, Janssen EM, Wise-Draper TM, Conforti L. Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients. Front Pharmacol 2021;12:742862. [PMID: 34512366 DOI: 10.3389/fphar.2021.742862] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis 2021;26:512-33. [PMID: 34510317 DOI: 10.1007/s10495-021-01687-9] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
210 Xie Y, Olkhov-Mitsel E, Alminawi S, Slodkowska E, Downes MR. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. Pathol Res Pract 2021;226:153607. [PMID: 34509050 DOI: 10.1016/j.prp.2021.153607] [Reference Citation Analysis]
211 Fan T, Pan S, Yang S, Hao B, Zhang L, Li D, Geng Q. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Front Immunol 2021;12:693062. [PMID: 34497605 DOI: 10.3389/fimmu.2021.693062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
212 Sun J, Tang Q, Zhang J, Chen G, Peng J, Chen L. Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. Front Mol Biosci 2021;8:717038. [PMID: 34497832 DOI: 10.3389/fmolb.2021.717038] [Reference Citation Analysis]
213 Dobre EG, Constantin C, Costache M, Neagu M. Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. J Pers Med 2021;11:901. [PMID: 34575678 DOI: 10.3390/jpm11090901] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
214 Wu X, Sun M, Yang Z, Lu C, Wang Q, Wang H, Deng C, Liu Y, Yang Y. The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front Cell Dev Biol 2021;9:686548. [PMID: 34490243 DOI: 10.3389/fcell.2021.686548] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
215 Liu SY, Zhu RH, Wang ZT, Tan W, Zhang L, Wang YQ, Dai FF, Yuan MQ, Zheng YJ, Yang DY, Wang FY, Xian S, He J, Zhang YW, Wu ML, Deng ZM, Hu M, Cheng YX, Liu YQ. Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning. J Oncol 2021;2021:5523749. [PMID: 34484333 DOI: 10.1155/2021/5523749] [Reference Citation Analysis]
216 Roda N, Blandano G, Pelicci PG. Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance. Cancers (Basel) 2021;13:4471. [PMID: 34503281 DOI: 10.3390/cancers13174471] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
217 Yamauchi T, Fujishima F, Hashimoto M, Tsunokake J, Akaishi R, Gokon Y, Ueki S, Ozawa Y, Fukutomi T, Okamoto H, Sato C, Taniyama Y, Nakamura T, Nakaya N, Kamei T, Sasano H. Necroptosis in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Its Correlation with Tumor-Infiltrating Lymphocytes. Cancers (Basel) 2021;13:4473. [PMID: 34503283 DOI: 10.3390/cancers13174473] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
218 Liu X, Xu Y, Yin L, Hou Y, Zhao S. Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl2 Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. Int J Nanomedicine 2021;16:5675-92. [PMID: 34456564 DOI: 10.2147/IJN.S318363] [Reference Citation Analysis]
219 An HJ, Chon HJ, Kim C. Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. Int J Mol Sci 2021;22:9414. [PMID: 34502325 DOI: 10.3390/ijms22179414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
220 Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology 2021;10:1960729. [PMID: 34434611 DOI: 10.1080/2162402X.2021.1960729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
221 Liu X, Shang X, Li J, Zhang S. The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer. Front Cell Dev Biol 2021;9:707143. [PMID: 34422829 DOI: 10.3389/fcell.2021.707143] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
222 Pradip, Jennifer A, Nandini D. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime. Int J Mol Sci 2021;22:9121. [PMID: 34502029 DOI: 10.3390/ijms22179121] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
223 Abken H. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. Hum Gene Ther 2021;32:1011-28. [PMID: 34405686 DOI: 10.1089/hum.2021.165] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
224 Tang D, Huang W, Yang Z, Wu X, Sang X, Wang K, Cao G. Identification and validation of 12 immune-related genes as a prognostic signature for colon adenocarcinoma. J Biochem Mol Toxicol 2021;:e22852. [PMID: 34396630 DOI: 10.1002/jbt.22852] [Reference Citation Analysis]
225 Mahaki H, Saeed Modaghegh MH, Nasr Isfahani Z, Amir Daddost R, Molaei P, Ahmadyousefi Y, Vahidzadeh M, Lotfiane E, Tanzadehpanah H. The Role of Peptide-Based Tumor Vaccines on Cytokines of Adaptive Immunity: A Review. Int J Pept Res Ther 2021;27:2527-42. [DOI: 10.1007/s10989-021-10270-4] [Reference Citation Analysis]
226 Du W, Frankel TL, Green M, Zou W. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol 2021. [PMID: 34385592 DOI: 10.1038/s41423-021-00735-3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
227 Pollari M, Leivonen SK, Leppä S. Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features. Cancers (Basel) 2021;13:4049. [PMID: 34439203 DOI: 10.3390/cancers13164049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
228 Du JW, Li GQ, Li YS, Qiu XG. Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma. Sci Rep 2021;11:16239. [PMID: 34376710 DOI: 10.1038/s41598-021-90538-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
229 Chen C, Sheng Y. Prognostic Impact of MITD1 and Associates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma. Technol Cancer Res Treat 2021;20:15330338211036233. [PMID: 34346239 DOI: 10.1177/15330338211036233] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Cen X, Huang Y, Lu Z, Shao W, Zhuo C, Bao C, Feng S, Wei C, Tang X, Cen L, Guo W, Tian X, Tang Q, Huang X. LncRNA IGFL2-AS1 Promotes the Proliferation, Migration, and Invasion of Colon Cancer Cells and is Associated with Patient Prognosis. Cancer Manag Res 2021;13:5957-68. [PMID: 34377016 DOI: 10.2147/CMAR.S313775] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
231 Farias A, Soto A, Puttur F, Goldin CJ, Sosa S, Gil C, Goldbaum FA, Berguer PM. A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment. Sci Rep 2021;11:15406. [PMID: 34321536 DOI: 10.1038/s41598-021-94837-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
232 Sun J, Zhang J, Hu H, Qin H, Liao X, Wang F, Zhang W, Yin Q, Su X, He Y, Li W, Wang K, Li Q. Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer. J Cancer Res Clin Oncol 2021. [PMID: 34291357 DOI: 10.1007/s00432-021-03735-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
233 Švajger U, Tešić N, Rožman P. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ. Int Immunopharmacol 2021;99:107978. [PMID: 34298399 DOI: 10.1016/j.intimp.2021.107978] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
234 Sun X, Chen Q, Zhang L, Chen J, Zhang X. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines. Math Biosci Eng 2021;18:6262-87. [PMID: 34517533 DOI: 10.3934/mbe.2021313] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
235 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
236 Hoffmann E, Paulsen F, Schaedle P, Zips D, Gani C, Rammensee HG, Gouttefangeas C, Eckert F. Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunol Immunother 2021. [PMID: 34269847 DOI: 10.1007/s00262-021-03002-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Soongsathitanon J, Jamjuntra P, Sumransub N, Yangngam S, De la Fuente M, Landskron G, Thuwajit P, Hermoso MA, Thuwajit C. Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer. J Immunol Res 2021;2021:8840066. [PMID: 34337083 DOI: 10.1155/2021/8840066] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
238 Wu CC, Chiang CY, Liu SJ, Chen HW. A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. Biomedicines 2021;9:806. [PMID: 34356870 DOI: 10.3390/biomedicines9070806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Wu C, Duan Y, Gong S, Kallendrusch S, Schopow N, Osterhoff G. Integrative and Comprehensive Pancancer Analysis of Regulator of Chromatin Condensation 1 (RCC1). Int J Mol Sci 2021;22:7374. [PMID: 34298996 DOI: 10.3390/ijms22147374] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
240 Lv L, Wei Q, Wang Z, Zhao Y, Chen N, Yi Q. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. Front Bioeng Biotechnol 2021;9:690186. [PMID: 34307322 DOI: 10.3389/fbioe.2021.690186] [Reference Citation Analysis]
241 Jiang J, Zhan X, Xu G, Liang T, Yu C, Liao S, Chen L, Huang S, Sun X, Yi M, Zhang Z, Yao Y, Liu C. Glycolysis- and immune-related novel prognostic biomarkers of Ewing's sarcoma: glucuronic acid epimerase and triosephosphate isomerase 1. Aging (Albany NY) 2021;13:17516-35. [PMID: 34233293 DOI: 10.18632/aging.203242] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
242 Hwang J, Zhang W, Park HB, Yadav D, Jeon YH, Jin JO. Escherichia coli adhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis. J Immunother Cancer 2021;9:e002666. [PMID: 34230112 DOI: 10.1136/jitc-2021-002666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
243 Park KS, Svennerholm K, Crescitelli R, Lässer C, Gribonika I, Lötvall J. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles 2021;10:e12120. [PMID: 34262675 DOI: 10.1002/jev2.12120] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
244 Zhang LY, Zhang JG, Yang X, Cai MH, Zhang CW, Hu ZM. Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery. Curr Top Med Chem 2020;20:2789-800. [PMID: 33076809 DOI: 10.2174/1568026620666201019111524] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
245 Chen Y, Sun Z, Chen W, Liu C, Chai R, Ding J, Liu W, Feng X, Zhou J, Shen X, Huang S, Xu Z. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning. Front Immunol 2021;12:685992. [PMID: 34262565 DOI: 10.3389/fimmu.2021.685992] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
246 Xu X, Li N, Wang D, Chen W, Fan Y. Clinical Relevance of PD-L1 Expression and CD8+ T Cells' Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma. Front Oncol 2021;11:683432. [PMID: 34249733 DOI: 10.3389/fonc.2021.683432] [Reference Citation Analysis]
247 Hu S, Hu Z, Qin J, Lin C, Jiang X. In silico analysis identifies neuropilin-1 as a potential therapeutic target for SARS-Cov-2 infected lung cancer patients. Aging (Albany NY) 2021;13:15770-84. [PMID: 34168096 DOI: 10.18632/aging.203159] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
248 Shang C, Huang J, Guo H. Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration. Front Cell Dev Biol 2021;9:677831. [PMID: 34249930 DOI: 10.3389/fcell.2021.677831] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
249 Zhang Q, Dai J, Song Z, Guo Y, Deng S, Yu Y, Li T, Zhang Y. Anti-Inflammatory Dipeptide, a Metabolite from Ambioba Secretion, Protects Cerebral Ischemia Injury by Blocking Apoptosis Via p-JNK/Bax Pathway. Front Pharmacol 2021;12:689007. [PMID: 34220513 DOI: 10.3389/fphar.2021.689007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Xu S, Yan X, Dai G, Luo C. A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy. Front Oncol 2021;11:692403. [PMID: 34178691 DOI: 10.3389/fonc.2021.692403] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Pezeshki PS, Mahdavi Sharif P, Rezaei N. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opin Biol Ther 2021;:1-16. [PMID: 33984254 DOI: 10.1080/14712598.2021.1929919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Cui Z, Xu D, Zhang F, Sun J, Song L, Ye W, Zeng J, Zhou M, Ruan Z, Zhang L, Ren R. CD47 blockade enhances therapeutic efficacy of cisplatin against lung carcinoma in a murine model. Exp Cell Res 2021;405:112677. [PMID: 34111474 DOI: 10.1016/j.yexcr.2021.112677] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
253 Kaplaneris N, Son J, Mendive-Tapia L, Kopp A, Barth ND, Maksso I, Vendrell M, Ackermann L. Chemodivergent manganese-catalyzed C-H activation: modular synthesis of fluorogenic probes. Nat Commun 2021;12:3389. [PMID: 34099672 DOI: 10.1038/s41467-021-23462-9] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
254 Wang T, Jin J, Qian C, Lou J, Lin J, Xu A, Xia K, Jin L, Liu B, Tao H, Yang Z, Yu W. Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment. Cancer Cell Int 2021;21:295. [PMID: 34098945 DOI: 10.1186/s12935-021-02003-w] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
255 Wang M, Li H, Huang B, Chen S, Cui R, Sun ZJ, Zhang M, Sun T. An Ultra-Stable, Oxygen-Supply Nanoprobe Emitting in Near-Infrared-II Window to Guide and Enhance Radiotherapy by Promoting Anti-Tumor Immunity. Adv Healthc Mater 2021;10:e2100090. [PMID: 33885213 DOI: 10.1002/adhm.202100090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
256 Xie Q, Ding J, Chen Y. Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. Acta Pharm Sin B 2021;11:1365-78. [PMID: 34221857 DOI: 10.1016/j.apsb.2021.03.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
257 Mehanny M, Lehr CM, Fuhrmann G. Extracellular vesicles as antigen carriers for novel vaccination avenues. Adv Drug Deliv Rev 2021;173:164-80. [PMID: 33775707 DOI: 10.1016/j.addr.2021.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
258 Chirivì M, Maiullari F, Milan M, Presutti D, Cordiglieri C, Crosti M, Sarnicola ML, Soluri A, Volpi M, Święszkowski W, Prati D, Rizzi M, Costantini M, Seliktar D, Parisi C, Bearzi C, Rizzi R. Tumor Extracellular Matrix Stiffness Promptly Modulates the Phenotype and Gene Expression of Infiltrating T Lymphocytes. Int J Mol Sci 2021;22:5862. [PMID: 34070750 DOI: 10.3390/ijms22115862] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
259 Zhang W, Li C, Wu F, Li N, Wang Y, Hu Y, Fang T, Yuan H, He H. Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma. Front Mol Biosci 2021;8:689037. [PMID: 34124165 DOI: 10.3389/fmolb.2021.689037] [Reference Citation Analysis]
260 Chang Z, Jian P, Zhang Q, Liang W, Zhou K, Hu Q, Liu Y, Liu R, Zhang L. Tannins in Terminalia bellirica inhibit hepatocellular carcinoma growth by regulating EGFR-signaling and tumor immunity. Food Funct 2021;12:3720-39. [PMID: 33900343 DOI: 10.1039/d1fo00203a] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
261 Zhang Q, Guo Y, Zhu L, Liu X, Yang J, Li Y, Zhu X, Zhang C. A nucleic acid nanogel dually bears siRNA and CpG motifs for synergistic tumor immunotherapy. Biomater Sci 2021;9:4755-64. [PMID: 34036978 DOI: 10.1039/d1bm00531f] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
262 Xuan Y, Guan M, Zhang S. Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes. Theranostics 2021;11:7360-78. [PMID: 34158855 DOI: 10.7150/thno.58413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
263 Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. The antigen-binding moiety in the driver's seat of CARs. Med Res Rev 2021. [PMID: 34028069 DOI: 10.1002/med.21818] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
264 Feng Z, Qian H, Li K, Lou J, Wu Y, Peng C. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:676291. [PMID: 34095229 DOI: 10.3389/fmolb.2021.676291] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
265 Gao C, Xu YJ, Qi L, Bao YF, Zhang L, Zheng L. CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol Toxicol 2021. [PMID: 34018092 DOI: 10.1007/s10565-021-09613-0] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
266 Zhou Q, Zhou J, Fan J. Expression and Prognostic Value of ARID5A and its Correlation With Tumor-Infiltrating Immune Cells in Glioma. Front Oncol 2021;11:638803. [PMID: 34094918 DOI: 10.3389/fonc.2021.638803] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
267 Alghamri MS, McClellan BL, Hartlage MS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Front Pharmacol 2021;12:680021. [PMID: 34084145 DOI: 10.3389/fphar.2021.680021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
268 Zhang K, Ping L, Ou X, Bazhabayi M, Xiao X. A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery. J Pers Med 2021;11:413. [PMID: 34069272 DOI: 10.3390/jpm11050413] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 Farahani N, Mohagheghi F, Mosayebi G, Ghazavi A, Ganji A. Reduced IL-37 gene expression and CD8 T lymphocytes in patients with metastatic breast cancer. Breast Dis 2021. [PMID: 34024810 DOI: 10.3233/BD-201055] [Reference Citation Analysis]
270 Turbitt WJ, Boi SK, Gibson JT, Orlandella RM, Norian LA. Diet-Induced Obesity Impairs Outcomes and Induces Multi-Factorial Deficiencies in Effector T Cell Responses Following Anti-CTLA-4 Combinatorial Immunotherapy in Renal Tumor-Bearing Mice. Cancers (Basel) 2021;13:2295. [PMID: 34064933 DOI: 10.3390/cancers13102295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Li J, Zhou L, Liu Y, Yang L, Jiang D, Li K, Xie S, Wang X, Wang S. Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer. Front Oncol 2021;11:674394. [PMID: 33996604 DOI: 10.3389/fonc.2021.674394] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
272 Gao T, Zhang Z, Liang S, Fu S, Mu W, Guan L, Liu Y, Chu Q, Fang Y, Liu Y, Zhang N. Reshaping Antitumor Immunity with Chemo‐Photothermal Integrated Nanoplatform to Augment Checkpoint Blockade‐Based Cancer Therapy. Adv Funct Mater 2021;31:2100437. [DOI: 10.1002/adfm.202100437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
273 Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, Drake A, Tang M, Wall P, Bernados D, Leung L, Ophir E, Alteber Z, Cojocaru G, Galperin M, Frenkel M, White M, Hunter J, Liang SC, Kotturi MF. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother 2021. [PMID: 33903974 DOI: 10.1007/s00262-021-02921-8] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
274 Isvoranu G, Surcel M, Munteanu AN, Bratu OG, Ionita-Radu F, Neagu MT, Chiritoiu-Butnaru M. Therapeutic potential of interleukin-15 in cancer (Review). Exp Ther Med 2021;22:675. [PMID: 33986840 DOI: 10.3892/etm.2021.10107] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
275 Wei M, Xu J, Hua J, Meng Q, Liang C, Liu J, Zhang B, Wang W, Yu X, Shi S. From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors. Front Immunol 2021;12:654660. [PMID: 33968055 DOI: 10.3389/fimmu.2021.654660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Jiang J, Liu D, Xu G, Liang T, Yu C, Liao S, Chen L, Huang S, Sun X, Yi M, Zhang Z, Lu Z, Wang Z, Chen J, Chen T, Li H, Yao Y, Chen W, Guo H, Liu C, Zhan X. TRIM68, PIKFYVE, and DYNLL2: The Possible Novel Autophagy- and Immunity-Associated Gene Biomarkers for Osteosarcoma Prognosis. Front Oncol 2021;11:643104. [PMID: 33968741 DOI: 10.3389/fonc.2021.643104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
277 Zhu P, Qian J, Xu Z, Meng C, Zhu W, Ran F, Zhang W, Zhang Y, Ling Y. Overview of piperlongumine analogues and their therapeutic potential. Eur J Med Chem 2021;220:113471. [PMID: 33930801 DOI: 10.1016/j.ejmech.2021.113471] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
278 Shi Y, Li D, He C, Chen X. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy. Macromol Biosci 2021;21:e2100049. [PMID: 33871152 DOI: 10.1002/mabi.202100049] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
279 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
280 Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer 2021;9:e002051. [PMID: 33849925 DOI: 10.1136/jitc-2020-002051] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
281 Garutti M, Bonin S, Buriolla S, Bertoli E, Pizzichetta MA, Zalaudek I, Puglisi F. Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers (Basel) 2021;13:1819. [PMID: 33920288 DOI: 10.3390/cancers13081819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
282 Kumar V, Giacomantonio MA, Gujar S. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy. Viruses 2021;13:654. [PMID: 33920168 DOI: 10.3390/v13040654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 D'mello KP, Zhao L, Kaser EC, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma. Med Oncol 2021;38:56. [PMID: 33835307 DOI: 10.1007/s12032-021-01504-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
284 Yagi H, Nakaguro M, Ito M, Okumura Y, Takahashi S, Aoshima Y, Enomoto Y, Meguro S, Kawasaki H, Kosugi I, Shimoyama Y, Ogawa H, Tateyama H, Iwashita T. Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma. Pathol Int 2021;71:453-62. [PMID: 33819365 DOI: 10.1111/pin.13099] [Reference Citation Analysis]
285 Mojsilovic S, Mojsilovic SS, Bjelica S, Santibanez JF. Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership. Dev Dyn 2021. [PMID: 33797140 DOI: 10.1002/dvdy.339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
286 Supabphol S, Li L, Goedegebuure SP, Gillanders WE. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opin Investig Drugs 2021;30:529-41. [PMID: 33641576 DOI: 10.1080/13543784.2021.1896702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
287 Zhou Y, Zhang L, Song S, Xu L, Yan Y, Wu H, Tong X, Yan H. Elevated GAS2L3 Expression Correlates With Poor Prognosis in Patients With Glioma: A Study Based on Bioinformatics and Immunohistochemical Analysis. Front Genet 2021;12:649270. [PMID: 33859674 DOI: 10.3389/fgene.2021.649270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Wang Y, Sun H, Zhu N, Wu X, Sui Z, Gong L, Yu Z. Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma. Front Oncol 2021;11:640080. [PMID: 33854974 DOI: 10.3389/fonc.2021.640080] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
289 Chan-Zapata I, Segura-Campos MR. Honey and its protein components: Effects in the cancer immunology. J Food Biochem 2021;45:e13613. [PMID: 33768550 DOI: 10.1111/jfbc.13613] [Reference Citation Analysis]
290 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
291 Craig DJ, Nanavaty NS, Devanaboyina M, Stanbery L, Hamouda D, Edelman G, Dworkin L, Nemunaitis JJ. The abscopal effect of radiation therapy. Future Oncol 2021;17:1683-94. [PMID: 33726502 DOI: 10.2217/fon-2020-0994] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
292 Cho S, Kim SB, Lee Y, Song EC, Kim U, Kim HY, Suh JH, Goughnour PC, Kim Y, Yoon I, Shin NY, Kim D, Kim IK, Kang CY, Jang SY, Kim MH, Kim S. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1. J Immunother Cancer 2020;8:e000277. [PMID: 32461342 DOI: 10.1136/jitc-2019-000277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
293 Gülich AF, Rica R, Tizian C, Viczenczova C, Khamina K, Faux T, Hainberger D, Penz T, Bosselut R, Bock C, Laiho A, Elo LL, Bergthaler A, Ellmeier W, Sakaguchi S. Complex Interplay Between MAZR and Runx3 Regulates the Generation of Cytotoxic T Lymphocyte and Memory T Cells. Front Immunol 2021;12:535039. [PMID: 33815354 DOI: 10.3389/fimmu.2021.535039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
294 Wang G, Zhang M, Cheng M, Wang X, Li K, Chen J, Chen Z, Chen S, Chen J, Xiong G, Xu X, Wang C, Chen D. Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Cancer Lett 2021;507:55-69. [PMID: 33741424 DOI: 10.1016/j.canlet.2021.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer 2021;20:52. [PMID: 33722265 DOI: 10.1186/s12943-021-01339-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
296 Goggi JL, Hartimath SV, Xuan TY, Khanapur S, Jieu B, Chin HX, Ramasamy B, Cheng P, Rong TJ, Fong YF, Yuen TY, Msallam R, Chacko AM, Renia L, Johannes C, Hwang YY, Robins EG. Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer. Mol Imaging Biol 2021;23:714-23. [PMID: 33713000 DOI: 10.1007/s11307-021-01596-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
297 Chhabra G, Singh CK, Amiri D, Akula N, Ahmad N. Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment. Molecules 2021;26:1343. [PMID: 33802331 DOI: 10.3390/molecules26051343] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
298 Hernández-Barranco A, Nogués L, Peinado H. Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches? Front Cell Dev Biol 2021;9:625221. [PMID: 33738282 DOI: 10.3389/fcell.2021.625221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
299 Dong X, Song J, Chen B, Qi Y, Jiang W, Li H, Zheng D, Wang Y, Zhang X, Liu H. Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Front Oncol 2020;10:592811. [PMID: 33718105 DOI: 10.3389/fonc.2020.592811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Liang R, Zhu X, Lan T, Ding D, Zheng Z, Chen T, Huang Y, Liu J, Yang X, Shao J, Wei H, Wei B. TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer. Cancer Immunol Immunother 2021;70:2781-93. [PMID: 33634371 DOI: 10.1007/s00262-021-02886-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
301 Medda A, Duca D, Chiocca S. Human Papillomavirus and Cellular Pathways: Hits and Targets. Pathogens 2021;10:262. [PMID: 33668730 DOI: 10.3390/pathogens10030262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Zhang J, Yu S, Hu W, Wang M, Abudoureyimu D, Luo D, Li T, Long L, Zeng H, Cheng C, Lei Z, Teng J, Kang X. Comprehensive Analysis of Cell Population Dynamics and Related Core Genes During Vitiligo Development. Front Genet 2021;12:627092. [PMID: 33679890 DOI: 10.3389/fgene.2021.627092] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
303 Tian L, Wang S, Jiang S, Liu Z, Wan X, Yang C, Zhang L, Zheng Z, Wang B, Li L. Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model. Int Immunopharmacol 2021;94:107441. [PMID: 33611060 DOI: 10.1016/j.intimp.2021.107441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
304 Mahdevar E, Safavi A, Abiri A, Kefayat A, Hejazi SH, Miresmaeili SM, Iranpur Mobarakeh V. Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches. J Biomol Struct Dyn 2021;:1-18. [PMID: 33599191 DOI: 10.1080/07391102.2021.1883111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Kim D, Lee S, Na K. Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. Small 2021;17:e2006650. [PMID: 33590726 DOI: 10.1002/smll.202006650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
306 Li X, Sun L, Wang X, Wang N, Xu K, Jiang X, Xu S. A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma. Front Mol Biosci 2021;8:632837. [PMID: 33665208 DOI: 10.3389/fmolb.2021.632837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
307 Huang H, Yang W, Hu J, Jiang Y, Wang J, Shi C, Kang Y, Wang D, Wang C, Yang G. Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. Parasite Immunol 2021;43:e12825. [PMID: 33507547 DOI: 10.1111/pim.12825] [Reference Citation Analysis]
308 Pan C, Wang Y, Liu Q, Hu Y, Fu J, Xie X, Zhang S, Xi M, Wen J. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. Oncoimmunology 2021;10:1883890. [PMID: 33628625 DOI: 10.1080/2162402X.2021.1883890] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
309 Chulpanova DS, Gilazieva ZE, Kletukhina SK, Aimaletdinov AM, Garanina EE, James V, Rizvanov AA, Solovyeva VV. Cytochalasin B-Induced Membrane Vesicles from Human Mesenchymal Stem Cells Overexpressing IL2 Are Able to Stimulate CD8+ T-Killers to Kill Human Triple Negative Breast Cancer Cells. Biology (Basel) 2021;10:141. [PMID: 33579033 DOI: 10.3390/biology10020141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
310 Zhao H, Wang C, Yang Y, Sun Y, Wei W, Wang C, Wan L, Zhu C, Li L, Huang G, Liu J. ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents. J Nanobiotechnology 2021;19:42. [PMID: 33563286 DOI: 10.1186/s12951-021-00785-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
311 Ayala-Mar S, Donoso-Quezada J, González-Valdez J. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. J Immunol Res 2021;2021:8839978. [PMID: 33628854 DOI: 10.1155/2021/8839978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
312 Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers (Basel) 2021;13:658. [PMID: 33562138 DOI: 10.3390/cancers13040658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
313 Dong Y, Lin L, Zeng C, He Z, Xu H. CD3D has the Potential to be a Prognostic Factor for Endometrial Carcinoma and an Indicator of Tumor Immune Microenvironment Regulation: a Study based on TCGA Data Mining. Indian J Gynecol Oncolog 2021;19. [DOI: 10.1007/s40944-021-00498-9] [Reference Citation Analysis]
314 Li W, Jin X, Guo S, Xu F, Su X, Jiang X, Wang G. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of colorectal cancer. Aging (Albany NY) 2021;13:5506-24. [PMID: 33536348 DOI: 10.18632/aging.202479] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 Nikolopoulou PA, Koufaki MA, Kostourou V. The Adhesome Network: Key Components Shaping the Tumour Stroma. Cancers (Basel) 2021;13:525. [PMID: 33573141 DOI: 10.3390/cancers13030525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
316 Zhang Y, Dong X, Wang Y, Wang L, Han G, Jin L, Fan Y, Xu G, Yuan D, Zheng J, Guo X, Gao P. Overexpression of LncRNA BM466146 Predicts Better Prognosis of Breast Cancer. Front Oncol 2020;10:628757. [PMID: 33585256 DOI: 10.3389/fonc.2020.628757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
317 Zhou H, Yang J, Tian J, Wang S. CD8+ T Lymphocytes: Crucial Players in Sjögren's Syndrome. Front Immunol 2020;11:602823. [PMID: 33584670 DOI: 10.3389/fimmu.2020.602823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
318 Coronado E, Yañez Y, Vidal E, Rubio L, Vera-Sempere F, Cañada-Martínez AJ, Panadero J, Cañete A, Ladenstein R, Castel V, Font de Mora J. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets. Mol Oncol 2021;15:364-80. [PMID: 33252831 DOI: 10.1002/1878-0261.12868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Tsogas FK, Majerczyk D, Hart PC. Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer. Int J Mol Sci 2021;22:E867. [PMID: 33467127 DOI: 10.3390/ijms22020867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
320 Chen T, Yang P, Jia Y. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review). Int J Mol Med 2021;47:13. [PMID: 33448320 DOI: 10.3892/ijmm.2021.4846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
321 Zhang R, Li T, Wang W, Gan W, Lv S, Zeng Z, Hou Y, Yan Z, Yang M. Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis. Front Oncol 2020;10:594098. [PMID: 33425745 DOI: 10.3389/fonc.2020.594098] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
322 Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today 2021;26:951-67. [PMID: 33450394 DOI: 10.1016/j.drudis.2021.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
323 Yu Q, Jobin C, Thomas RM. Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut. Neoplasia 2021;23:246-56. [PMID: 33418277 DOI: 10.1016/j.neo.2020.12.008] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
324 Fang W, Zhou T, Shi H, Yao M, Zhang D, Qian H, Zeng Q, Wang Y, Jin F, Chai C, Chen T. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion. J Exp Clin Cancer Res 2021;40:4. [PMID: 33390170 DOI: 10.1186/s13046-020-01786-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
325 Liu Y, Jia H, Han X, Wu F. Endoplasmic reticulum-targeting nanomedicines for cancer therapy. Smart Materials in Medicine 2021;2:334-49. [DOI: 10.1016/j.smaim.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
326 Fang X, Wu X, Li Z, Jiang L, Lo WS, Chen G, Gu Y, Wong WT. Biomimetic Anti-PD-1 Peptide-Loaded 2D FePSe3 Nanosheets for Efficient Photothermal and Enhanced Immune Therapy with Multimodal MR/PA/Thermal Imaging. Adv Sci (Weinh) 2021;8:2003041. [PMID: 33511018 DOI: 10.1002/advs.202003041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
327 Rastogi A, Robert PA, Halle S, Meyer-Hermann M. Evaluation of CD8 T cell killing models with computer simulations of 2-photon imaging experiments. PLoS Comput Biol 2020;16:e1008428. [PMID: 33370254 DOI: 10.1371/journal.pcbi.1008428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
328 Cess CG, Finley SD. Multi-scale modeling of macrophage-T cell interactions within the tumor microenvironment. PLoS Comput Biol 2020;16:e1008519. [PMID: 33362239 DOI: 10.1371/journal.pcbi.1008519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
329 Shelton SE, Nguyen HT, Barbie DA, Kamm RD. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience 2021;24:101985. [PMID: 33490895 DOI: 10.1016/j.isci.2020.101985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
330 Dong X, Song J, Hu J, Zheng C, Zhang X, Liu H. T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAF V600E Mutation in Papillary Thyroid Carcinoma. Front Cell Dev Biol 2020;8:590898. [PMID: 33392186 DOI: 10.3389/fcell.2020.590898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Liu Y, Xia Y, Qiu CH. Functions of CD169 positive macrophages in human diseases (Review). Biomed Rep 2021;14:26. [PMID: 33408860 DOI: 10.3892/br.2020.1402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
332 Dong X, Yang Q, Gu J, Lv S, Song D, Chen D, Song J, Zhang X, Huang D. Identification and validation of L Antigen Family Member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. Int Immunopharmacol 2021;90:107267. [PMID: 33310661 DOI: 10.1016/j.intimp.2020.107267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 Cheng Y, Zhang X, Wang Z, Wang J. Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis. Front Oncol 2020;10:595082. [PMID: 33363026 DOI: 10.3389/fonc.2020.595082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
334 Mortezaee K. Redox tolerance and metabolic reprogramming in solid tumors. Cell Biol Int 2021;45:273-86. [PMID: 33236822 DOI: 10.1002/cbin.11506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
335 Checcoli A, Pol JG, Naldi A, Noel V, Barillot E, Kroemer G, Thieffry D, Calzone L, Stoll G. Dynamical Boolean Modeling of Immunogenic Cell Death. Front Physiol 2020;11:590479. [PMID: 33281620 DOI: 10.3389/fphys.2020.590479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
336 Lee DY, Im E, Yoon D, Lee YS, Kim GS, Kim D, Kim SH. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. Semin Cancer Biol 2020:S1044-579X(20)30258-3. [PMID: 33301862 DOI: 10.1016/j.semcancer.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
337 Oshi M, Tokumaru Y, Patel A, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Cancers (Basel) 2020;12:E3635. [PMID: 33291601 DOI: 10.3390/cancers12123635] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
338 Mirzaei S, Fekri HS, Hashemi F, Hushmandi K, Mohammadinejad R, Ashrafizadeh M, Zarrabi A, Garg M. Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacol Res 2021;164:105327. [PMID: 33276098 DOI: 10.1016/j.phrs.2020.105327] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
339 Chen J, Huang J. Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer. J Mater Res 2020;35:3296-303. [DOI: 10.1557/jmr.2020.321] [Reference Citation Analysis]
340 Gang H, Peng D, Hu Y, Tang S, Li S, Huang Q. Interleukin-9-secreting CD4+ T cells regulate CD8+ T cells cytotoxicity in patients with acute coronary syndromes. APMIS 2021;129:91-102. [PMID: 33113251 DOI: 10.1111/apm.13094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
341 Zhang E, He J, Zhang H, Shan L, Wu H, Zhang M, Song Y. Immune-Related Gene-Based Novel Subtypes to Establish a Model Predicting the Risk of Prostate Cancer. Front Genet 2020;11:595657. [PMID: 33281882 DOI: 10.3389/fgene.2020.595657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
342 Jiang S. Tet2 at the interface between cancer and immunity. Commun Biol 2020;3:667. [PMID: 33184433 DOI: 10.1038/s42003-020-01391-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
343 Gao X, Yamazaki Y, Pecori A, Tezuka Y, Ono Y, Omata K, Morimoto R, Nakamura Y, Satoh F, Sasano H. Histopathological Analysis of Tumor Microenvironment and Angiogenesis in Pheochromocytoma. Front Endocrinol (Lausanne) 2020;11:587779. [PMID: 33244312 DOI: 10.3389/fendo.2020.587779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
344 Liu HM, Ma LL, Cao B, Lin JZ, Han L, Li CY, Xu RC, Zhang DK. Progress in research into the role of abnormal glycosylation modification in tumor immunity. Immunol Lett 2021;229:8-17. [PMID: 33186635 DOI: 10.1016/j.imlet.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
345 Drijvers JM, Sharpe AH, Haigis MC. The effects of age and systemic metabolism on anti-tumor T cell responses. Elife 2020;9:e62420. [PMID: 33170123 DOI: 10.7554/eLife.62420] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
346 Wang SW, Su WH, Jia XM, Jiang HT, Huang BL, Dong WG. Role of cGAS-STING signaling pathway in colon cancer. Shijie Huaren Xiaohua Zazhi 2020; 28(21): 1084-1089 [DOI: 10.11569/wcjd.v28.i21.1084] [Reference Citation Analysis]
347 Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, Wang Y. Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. Int J Mol Sci 2020;21:E8363. [PMID: 33171818 DOI: 10.3390/ijms21218363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
348 Mohammadian Haftcheshmeh S, Zamani P, Mashreghi M, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer. Biotechnol Prog 2021;37:e3095. [PMID: 33118322 DOI: 10.1002/btpr.3095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
349 Islas-Vazquez L, Aguilar-Cazares D, Galicia-Velasco M, Rumbo-Nava U, Meneses-Flores M, Luna-Rivero C, Lopez-Gonzalez JS. IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. Biology (Basel) 2020;9:E376. [PMID: 33167343 DOI: 10.3390/biology9110376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
350 Ramalhete L, Araújo R, Calado CR. Discriminating B and T-lymphocyte from its molecular profile acquired in a label-free and high-throughput method. Vibrational Spectroscopy 2020;111:103177. [DOI: 10.1016/j.vibspec.2020.103177] [Reference Citation Analysis]
351 Liu S, Wang F, Tan W, Zhang L, Dai F, Wang Y, Fan Y, Yuan M, Yang D, Zheng Y, Deng Z, Liu Y, Cheng Y. CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC). Cancer Cell Int 2020;20:519. [PMID: 33117084 DOI: 10.1186/s12935-020-01603-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
352 Zhang W, Hwang J, Park HB, Lim SM, Go S, Kim J, Choi I, You S, Jin JO. Human Peripheral Blood Dendritic Cell and T Cell Activation by Codium fragile Polysaccharide. Mar Drugs 2020;18:E535. [PMID: 33120897 DOI: 10.3390/md18110535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
353 Kim WS, Han JM, Song HY, Byun EH, Seo HS, Byun EB. Edible Oxya chinensis sinuosa-Derived Protein as a Potential Nutraceutical for Anticancer Immunity Improvement. Nutrients 2020;12:E3236. [PMID: 33105813 DOI: 10.3390/nu12113236] [Reference Citation Analysis]
354 Makau MC, Powell J, Prendergast J, Latré de Laté P, Morrison LJ, Fisch A, Gathura P, Kitala P, Connelley T, Toye P. Inverted CD4+/CD8+ T cell ratio in Boran (Bos indicus) cattle. Vet Immunol Immunopathol 2020;230:110126. [PMID: 33080530 DOI: 10.1016/j.vetimm.2020.110126] [Reference Citation Analysis]
355 Zhou W, Zhang C, Zhang D, Peng J, Ma S, Wang X, Guan X, Li P, Li D, Jia G, Jia W. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. J Neurooncol 2020;149:473-87. [PMID: 33034841 DOI: 10.1007/s11060-020-03636-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
356 Shi J, Wang K, Xiong Z, Yuan C, Wang C, Cao Q, Yu H, Meng X, Xie K, Cheng Z, Yang H, Chen K, Zhang X. Impact of inflammation and immunotherapy in renal cell carcinoma. Oncol Lett 2020;20:272. [PMID: 33014151 DOI: 10.3892/ol.2020.12135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Wang H, Zhou H, Xu J, Lu Y, Ji X, Yao Y, Chao H, Zhang J, Zhang X, Yao S, Wu Y, Wan J. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett 2021;496:134-43. [PMID: 33022290 DOI: 10.1016/j.canlet.2020.09.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
358 Sabbatino F, Liguori L, Polcaro G, Salvato I, Caramori G, Salzano FA, Casolaro V, Stellato C, Col JD, Pepe S. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients. Int J Mol Sci 2020;21:E7295. [PMID: 33023239 DOI: 10.3390/ijms21197295] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
359 Zhang Y, Dong X, Bai L, Shang X, Zeng Y. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett. 2020;20:317. [PMID: 33133253 DOI: 10.3892/ol.2020.12180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
360 Jacobsen-Pereira CH, Cardoso CC, Gehlen TC, Regina Dos Santos C, Santos-Silva MC. Immune response of Brazilian farmers exposed to multiple pesticides. Ecotoxicol Environ Saf 2020;202:110912. [PMID: 32800247 DOI: 10.1016/j.ecoenv.2020.110912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
361 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
362 Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, Monopoli A, Accetturi MP, Cantonetti M, Antonini Cappellini GC, De Galitiis F, Rosato A, Picozza M, Russo G, D'Atri S. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Front Immunol 2020;11:579894. [PMID: 33072126 DOI: 10.3389/fimmu.2020.579894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Du B, Du Q, Bai Y, Yu L, Wang Y, Huang J, Zheng M, Shen G, Zhou J, Yao H. Chemotherapy based on "Domino-effect" combined with immunotherapy amplifying the efficacy of an anti-metastatic treatment. J Mater Chem B 2020. [PMID: 32945310 DOI: 10.1039/d0tb01061h] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Li L, Yue HC, Han YW, Liu W, Xiong LG, Zhang JW. Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer. BMC Cancer 2020;20:893. [PMID: 32942998 DOI: 10.1186/s12885-020-07403-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
365 Xie Z, Peng M, Lu R, Meng X, Liang W, Li Z, Qiu M, Zhang B, Nie G, Xie N, Zhang H, Prasad PN. Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light Sci Appl 2020;9:161. [PMID: 33014356 DOI: 10.1038/s41377-020-00388-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 71] [Article Influence: 17.5] [Reference Citation Analysis]
366 Li Q, Liu X, Wang D, Wang Y, Lu H, Wen S, Fang J, Cheng B, Wang Z. Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. Int J Oral Sci 2020;12:24. [PMID: 32934197 DOI: 10.1038/s41368-020-00092-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
367 Tan HNC, Catedral LIG, San Juan MD. Prognostic Significance of Tumor-infiltrating Lymphocytes on Survival Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. J Immunother 2021;44:29-40. [PMID: 32909965 DOI: 10.1097/CJI.0000000000000331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
368 Keam S, Gill S, Ebert MA, Nowak AK, Cook AM. Enhancing the efficacy of immunotherapy using radiotherapy. Clin Transl Immunology 2020;9:e1169. [PMID: 32994997 DOI: 10.1002/cti2.1169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
369 Xu Z, Chokkalingam N, Tello-Ruiz E, Wise MC, Bah MA, Walker S, Tursi NJ, Fisher PD, Schultheis K, Broderick KE, Humeau L, Kulp DW, Weiner DB. A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control. Cancer Immunol Res 2020;8:1354-64. [PMID: 32913042 DOI: 10.1158/2326-6066.CIR-20-0061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
370 Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020;9:E2061. [PMID: 32917034 DOI: 10.3390/cells9092061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
371 Majumder D, Debnath R, Maiti D. IL-27 along with IL-28B ameliorates the pulmonary redox impairment, inflammation and immunosuppression in benzo(a)pyrene induced lung cancer bearing mice. Life Sci 2020;260:118384. [PMID: 32898529 DOI: 10.1016/j.lfs.2020.118384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
372 Kurup SP, Moioffer SJ, Pewe LL, Harty JT. p53 Hinders CRISPR/Cas9-Mediated Targeted Gene Disruption in Memory CD8 T Cells In Vivo. J Immunol 2020;205:2222-30. [PMID: 32887747 DOI: 10.4049/jimmunol.2000654] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
373 Fuchs N, Meta M, Schuppan D, Nuhn L, Schirmeister T. Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery. Cells 2020;9:E2021. [PMID: 32887380 DOI: 10.3390/cells9092021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
374 Zhou X, Qiu S, Nie L, Jin D, Jin K, Zheng X, Yang L, Wei Q. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling. Front Oncol 2020;10:1429. [PMID: 32974156 DOI: 10.3389/fonc.2020.01429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
375 Yu R, Jin L, Li F, Fujimoto M, Wei Q, Lin Z, Ren X, Jin Q, Li H, Meng F, Jin G. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner. J Dermatol Sci 2020;99:193-202. [PMID: 32859456 DOI: 10.1016/j.jdermsci.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
376 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
377 Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:337-48. [PMID: 32757055 DOI: 10.1007/s00262-020-02686-6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
378 Angelopoulou F, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 2021;41:33-42. [PMID: 32743706 DOI: 10.1007/s00296-020-04665-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
379 Alimardani V, Abolmaali SS, Tamaddon AM, Ashfaq M. Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy. Drug Deliv Transl Res 2021;11:788-816. [PMID: 32740799 DOI: 10.1007/s13346-020-00819-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
380 Wu X, Hou P, Qiu Y, Wang Q, Lu X. Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma. Onco Targets Ther 2020;13:7531-43. [PMID: 32801772 DOI: 10.2147/OTT.S257050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
381 Sperb N, Tsesmelis M, Wirth T. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E5486. [PMID: 32752017 DOI: 10.3390/ijms21155486] [Cited by in Crossref: 16] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
382 Papaevangelou E, Smolarek D, Smith RA, Dasgupta P, Galustian C. Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model. Immunotargets Ther 2020;9:115-30. [PMID: 32802803 DOI: 10.2147/ITT.S257443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
383 Li M, Qin M, Song G, Deng H, Wang D, Wang X, Dai W, He B, Zhang H, Zhang Q. A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens. Asian J Pharm Sci 2021;16:97-109. [PMID: 33613733 DOI: 10.1016/j.ajps.2020.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
384 Lin X, Zhang J, Wang X, Lin G, Chen T. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer. Anticancer Drugs 2020;31:989-96. [PMID: 32694422 DOI: 10.1097/CAD.0000000000000972] [Reference Citation Analysis]
385 Sato Y, Tanaka S, Kinoshita M, Takemura S, Shinkawa H, Kokudo T, Hasegawa K, Tanaka H, Yoshimoto H, Mori A, Yamamura M, Sasaki M, Harada K, Kubo S. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy. J Hepatobiliary Pancreat Sci 2020;27:860-9. [PMID: 32506715 DOI: 10.1002/jhbp.788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
386 Mortezaee K. Immune escape: A critical hallmark in solid tumors. Life Sci 2020;258:118110. [PMID: 32698074 DOI: 10.1016/j.lfs.2020.118110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 44] [Article Influence: 11.5] [Reference Citation Analysis]
387 de Carvalho JTG, Da Silva Baldivia D, de Castro DTH, Dos Santos HF, Dos Santos CM, Oliveira AS, Alfredo TM, Vilharva KN, de Picoli Souza K, Dos Santos EL. The immunoregulatory function of polyphenols: implications in cancer immunity. J Nutr Biochem 2020;85:108428. [PMID: 32679443 DOI: 10.1016/j.jnutbio.2020.108428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
388 Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives. Int Immunopharmacol 2020;87:106807. [PMID: 32683299 DOI: 10.1016/j.intimp.2020.106807] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
389 Rus Bakarurraini NAA, Ab Mutalib NS, Jamal R, Abu N. The Landscape of Tumor-Specific Antigens in Colorectal Cancer. Vaccines (Basel) 2020;8:E371. [PMID: 32664247 DOI: 10.3390/vaccines8030371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
390 Xu DD, Ding M, Tong P, Chong YY, Gu WY, Li Y, Fang XJ, Li N. Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma. Oncol Rep 2020;44:897-908. [PMID: 32705278 DOI: 10.3892/or.2020.7679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
391 Cheng YQ, Wang SB, Liu JH, Jin L, Liu Y, Li CY, Su YR, Liu YR, Sang X, Wan Q, Liu C, Yang L, Wang ZC. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Prolif 2020;53:e12865. [PMID: 32588948 DOI: 10.1111/cpr.12865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
392 Edemir B. Identification of Prognostic Organic Cation and Anion Transporters in Different Cancer Entities by In Silico Analysis. Int J Mol Sci 2020;21:E4491. [PMID: 32599841 DOI: 10.3390/ijms21124491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
393 Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int J Mol Sci 2020;21:E4427. [PMID: 32580338 DOI: 10.3390/ijms21124427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
394 Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, Ramírez A, Sesma A, Torres-Ramón I, Yubero A, Pardo J, Martínez-Lostao L. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells 2020;9:E1525. [PMID: 32580514 DOI: 10.3390/cells9061525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
395 Aindelis G, Chlichlia K. Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria. Vaccines (Basel) 2020;8:E329. [PMID: 32575876 DOI: 10.3390/vaccines8020329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
396 Maharjan S, Cecen B, Zhang YS. 3D Immunocompetent Organ-on-a-Chip Models. Small Methods 2020;4:2000235. [PMID: 33072861 DOI: 10.1002/smtd.202000235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
397 Han X, Bai B, Zhou Q, Niu J, Yuan J, Zhang H, Jia J, Zhao W, Chen H. Dietary supplementation with polysaccharides from Ziziphus Jujuba cv. Pozao intervenes in immune response via regulating peripheral immunity and intestinal barrier function in cyclophosphamide-induced mice. Food Funct 2020;11:5992-6006. [PMID: 32697211 DOI: 10.1039/d0fo00008f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
398 Wang L, He Y, He T, Liu G, Lin C, Li K, Lu L, Cai K. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. Biomaterials 2020;255:120208. [PMID: 32569862 DOI: 10.1016/j.biomaterials.2020.120208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
399 Zhang L, Zhang H, Huang Y, Xi X, Sun Y. Expression of immune cell markers and tumor markers in patients with cervical cancer. Int J Gynecol Cancer 2020;30:969-74. [PMID: 32518078 DOI: 10.1136/ijgc-2020-001254] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
400 Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol 2021;33:7-15. [PMID: 32496557 DOI: 10.1093/intimm/dxaa037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
401 Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA, Solovyeva VV. Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. Front Cell Dev Biol 2020;8:402. [PMID: 32582698 DOI: 10.3389/fcell.2020.00402] [Cited by in Crossref: 15] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
402 de Paula RFO, Rosa IA, Gafanhão IFM, Fachi JL, Melero AMG, Roque AO, Boldrini VO, Ferreira LAB, Irazusta SP, Ceragioli HJ, de Oliveira EC. Reduced graphene oxide, but not carbon nanotubes, slows murine melanoma after thermal ablation using LED light in B16F10 lineage cells. Nanomedicine 2020;28:102231. [PMID: 32502697 DOI: 10.1016/j.nano.2020.102231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
403 Chen GG, Woo PYM, Ng SCP, Wong GKC, Chan DTM, van Hasselt CA, Tong MCF, Poon WS. Impact of metformin on immunological markers: Implication in its anti-tumor mechanism. Pharmacol Ther 2020;213:107585. [PMID: 32473961 DOI: 10.1016/j.pharmthera.2020.107585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
404 Hu Q, Egranov SD, Lin C, Yang L. Long noncoding RNA loss in immune suppression in cancer. Pharmacol Ther 2020;213:107591. [PMID: 32473960 DOI: 10.1016/j.pharmthera.2020.107591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
405 Olejarz W, Dominiak A, Żołnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. J Immunol Res 2020;2020:6272498. [PMID: 32537468 DOI: 10.1155/2020/6272498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
406 Kim DH, Seo J, Na K. pH-Sensitive Carbon Dots for Enhancing Photomediated Antitumor Immunity. Mol Pharmaceutics 2020;17:2532-45. [DOI: 10.1021/acs.molpharmaceut.0c00227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
407 White JM, Keinänen OM, Cook BE, Zeglis BM, Gibson HM, Viola NT. Removal of Fc Glycans from [89Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8+ T Cells. Mol Pharm 2020;17:2099-108. [PMID: 32330387 DOI: 10.1021/acs.molpharmaceut.0c00270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
408 Tao X, Wu X, Huang T, Mu D. Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing. Front Genet 2020;11:352. [PMID: 32457792 DOI: 10.3389/fgene.2020.00352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
409 da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World J Gastroenterol 2020; 26(17): 2040-2048 [PMID: 32536773 DOI: 10.3748/wjg.v26.i17.2040] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
410 Wang W, Thomas R, Sizova O, Su DM. Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review. Front Immunol 2020;11:773. [PMID: 32425946 DOI: 10.3389/fimmu.2020.00773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
411 Lidenge SJ, Tso FY, Ngalamika O, Kolape J, Ngowi JR, Mwaiselage J, Wood C, West JT. Lack of CD8+ T-cell co-localization with Kaposi's sarcoma-associated herpesvirus infected cells in Kaposi's sarcoma tumors. Oncotarget 2020;11:1556-72. [PMID: 32391124 DOI: 10.18632/oncotarget.27569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
412 Rana A, de Almeida FC, Paico Montero HA, Gonzales Carazas MM, Bortoluci KR, Sad S, Amarante-Mendes GP. RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified Listeria monocytogenes. Front Immunol 2020;11:536. [PMID: 32328060 DOI: 10.3389/fimmu.2020.00536] [Reference Citation Analysis]
413 Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, Gögenur I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer 2020;132:71-84. [PMID: 32334338 DOI: 10.1016/j.ejca.2020.03.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
414 Moldoveanu D, Pravongviengkham V, Best G, Martínez C, Hijal T, Meguerditchian AN, Lajoie M, Dumitra S, Watson I, Meterissian S. Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer. Ann Surg Oncol 2020;27:4028-34. [PMID: 32314154 DOI: 10.1245/s10434-020-08302-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
415 Abdolalipour E, Mahooti M, Salehzadeh A, Torabi A, Mohebbi SR, Gorji A, Ghaemi A. Evaluation of the antitumor immune responses of probiotic Bifidobacterium bifidum in human papillomavirus-induced tumor model. Microb Pathog 2020;145:104207. [PMID: 32325236 DOI: 10.1016/j.micpath.2020.104207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
416 Liu Q, Sun Y, Yin X, Li J, Xie J, Xie M, Wang K, Wu S, Li Y, Hussain M, Jiang B, Liu Y, Huang C, Tao J, Zhu J. Hyaluronidase-Functionalized Silica Nanocarrier for Enhanced Chemo-Immunotherapy through Inducing Immunogenic Cell Death. ACS Appl Bio Mater 2020;3:3378-89. [DOI: 10.1021/acsabm.0c00299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
417 Zhu Y, Xue J, Chen W, Bai S, Zheng T, He C, Guo Z, Jiang M, Du G, Sun X. Albumin-biomineralized nanoparticles to synergize phototherapy and immunotherapy against melanoma. J Control Release 2020;322:300-11. [PMID: 32240675 DOI: 10.1016/j.jconrel.2020.03.045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
418 Bujak JK, Szopa IM, Pingwara R, Kruczyk O, Krzemińska N, Mucha J, Majchrzak-Kuligowska K. The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors. Int J Mol Sci 2020;21:E2292. [PMID: 32225066 DOI: 10.3390/ijms21072292] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
419 Yuan K, Feng Y, Wang H, Zhao L, Wang W, Wang T, Feng Y, Huang G, Xu A. FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma. PeerJ 2020;8:e8654. [PMID: 32206449 DOI: 10.7717/peerj.8654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
420 Hoekstra ME, Bornes L, Dijkgraaf FE, Philips D, Pardieck IN, Toebes M, Thommen DS, van Rheenen J, Schumacher TNM. Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFNγ. Nat Cancer 2020;1:291-301. [PMID: 32566933 DOI: 10.1038/s43018-020-0036-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
421 Cao M, Wang Y, Wang D, Duan Y, Hong W, Zhang N, Shah W, Wang Y, Chen H. Increased High-Risk Human Papillomavirus Viral Load Is Associated With Immunosuppressed Microenvironment and Predicts a Worse Long-Term Survival in Cervical Cancer Patients. Am J Clin Pathol 2020;153:502-12. [PMID: 31819948 DOI: 10.1093/ajcp/aqz186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
422 Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev 2019;291:134-53. [PMID: 31402496 DOI: 10.1111/imr.12796] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
423 Almendros I, Martinez-garcia MA, Farré R, Gozal D. Obesity, sleep apnea, and cancer. Int J Obes 2020;44:1653-67. [DOI: 10.1038/s41366-020-0549-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
424 Adu-berchie K, Mooney DJ. Filmed over with CAR-T cells. Nat Biomed Eng 2020;4:142-3. [DOI: 10.1038/s41551-020-0517-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
425 Briquez PS, Hauert S, de Titta A, Gray LT, Alpar AT, Swartz MA, Hubbell JA. Engineering Targeting Materials for Therapeutic Cancer Vaccines. Front Bioeng Biotechnol. 2020;8:19. [PMID: 32117911 DOI: 10.3389/fbioe.2020.00019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
426 Liu Y, Guo J, Huang L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 2020;10:3099-117. [PMID: 32194857 DOI: 10.7150/thno.42998] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
427 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
428 Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, Ypsilantis P, Pappa A, Chlichlia K. Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei. Cancers (Basel) 2020;12:E368. [PMID: 32033490 DOI: 10.3390/cancers12020368] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
429 Jiang S, Wang S, Zhang L, Tian L, Li L, Liu Z, Dong Q, Lv X, Mu H, Zhang Q, Wang B. Hesperetin as an adjuvant augments protective anti-tumour immunity responses in B16F10 melanoma by stimulating cytotoxic CD8+ T cells. Scand J Immunol 2020;91:e12867. [PMID: 31975405 DOI: 10.1111/sji.12867] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
430 Mortezaee K. Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α. Life Sciences 2020;242:117145. [DOI: 10.1016/j.lfs.2019.117145] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
431 Sasson SC, Gordon CL, Christo SN, Klenerman P, Mackay LK. Local heroes or villains: tissue-resident memory T cells in human health and disease. Cell Mol Immunol 2020;17:113-22. [PMID: 31969685 DOI: 10.1038/s41423-019-0359-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
432 Shi W, Qiu Q, Tong Z, Guo W, Zou F, Feng Z, Wang Y, Huang W, Qian H. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells. Eur J Med Chem 2020;189:112051. [PMID: 31968280 DOI: 10.1016/j.ejmech.2020.112051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
433 Liu CC, Steen CB, Newman AM. Computational approaches for characterizing the tumor immune microenvironment. Immunology 2019;158:70-84. [PMID: 31347163 DOI: 10.1111/imm.13101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
434 Sulaieva O, Selezniov O, Shapochka D, Belemets N, Nechay O, Chereshneva Y, Tsomartova D, Ivanova M. Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. Heliyon 2020;6:e03077. [PMID: 31938743 DOI: 10.1016/j.heliyon.2019.e03077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
435 Steinel NC, Lee EM, Viggiano D, Capasso A, Lee MW. The renal adverse effects of cancer immunotherapy. J Nephrol 2020;33:467-81. [PMID: 31912436 DOI: 10.1007/s40620-019-00691-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
436 Lavoie S, Chun E, Bae S, Brennan CA, Gallini Comeau CA, Lang JK, Michaud M, Hoveyda HR, Fraser GL, Fuller MH, Layden BT, Glickman JN, Garrett WS. Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice. Gastroenterology 2020;158:1359-1372.e9. [PMID: 31917258 DOI: 10.1053/j.gastro.2019.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
437 Dong H, Xu X, Wang L, Mo R. Advances in living cell-based anticancer therapeutics. Biomater Sci 2020;8:2344-65. [DOI: 10.1039/d0bm00036a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
438 Bi Y, Wang M, Peng L, Ruan L, Zhou M, Hu Y, Chen J, Gao J. Photo/thermo-responsive and size-switchable nanoparticles for chemo-photothermal therapy against orthotopic breast cancer. Nanoscale Adv 2020;2:210-3. [DOI: 10.1039/c9na00652d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
439 Delmas D, Limagne E, Ghiringhelli F, Aires V. Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol. Food Chem Toxicol 2020;137:111091. [PMID: 31883989 DOI: 10.1016/j.fct.2019.111091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
440 Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, Bima C, Bracaccia ME, Lugli F, Lauretti L, Anile C, Gessi M, Colosimo C, Rindi G, Pontecorvi A, Korbonits M, De Marinis L. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine 2020;67:651-8. [PMID: 31875303 DOI: 10.1007/s12020-019-02145-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
441 Tang S, Zhou L, Liu Z, Zou L, Xiao M, Huang C, Xie Z, He H, Guo Y, Cao Y, Huang H, Wu X, Meng D, Ye L, Wu Y, Yang X, Zhou X. Ceria nanoparticles promoted the cytotoxic activity of CD8+ T cells by activating NF-κB signaling. Biomater Sci 2019;7:2533-44. [PMID: 30968875 DOI: 10.1039/c9bm00113a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
442 Li Q, Sun J, Cao Y, Liu B, Li L, Mohammadtursun N, Zhang H, Dong J, Wu J. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. Biomed Pharmacother 2020;123:109735. [PMID: 31864210 DOI: 10.1016/j.biopha.2019.109735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
443 Kurum A, Gao M, Tang L. Synthetic 3D scaffolds for cancer immunotherapy. Curr Opin Biotechnol 2020;65:1-8. [PMID: 31838435 DOI: 10.1016/j.copbio.2019.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
444 McGonagle D, Bragazzi NL, Amital H, Watad A. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. Autoimmun Rev. 2020;19:102456. [PMID: 31838166 DOI: 10.1016/j.autrev.2019.102456] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
445 Zhong X, Zhang Y, Wang L, Zhang H, Liu H, Liu Y. Cellular components in tumor microenvironment of neuroblastoma and the prognostic value. PeerJ 2019;7:e8017. [PMID: 31844563 DOI: 10.7717/peerj.8017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
446 Huang W, Wu C, Hsu Y, Chang C. Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy. International Journal of Hyperthermia 2019;36:1254-62. [DOI: 10.1080/02656736.2019.1699172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
447 Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J, Ahadi R. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol 2020;146:19-31. [PMID: 31734836 DOI: 10.1007/s00432-019-03080-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
448 Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett 2020;470:126-33. [PMID: 31730903 DOI: 10.1016/j.canlet.2019.11.009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 101] [Article Influence: 27.3] [Reference Citation Analysis]
449 Yamasuge W, Yamamoto Y, Fujigaki H, Hoshi M, Nakamoto K, Kunisawa K, Mouri A, Nabeshima T, Saito K. Indoleamine 2,3-dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma. Cancer Sci 2019;110:3061-7. [PMID: 31444833 DOI: 10.1111/cas.14179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
450 Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Kalofonos H, Liossis S. An MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatology 2020;59:1041-50. [DOI: 10.1093/rheumatology/kez361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
451 Subbarayan RS, Arnold L, Gomez JP, Thomas SM. The role of the innate and adaptive immune response in HPV-associated oropharyngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol 2019;4:508-12. [PMID: 31637294 DOI: 10.1002/lio2.300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
452 Zhang Y, Zheng L, Zhang L, Hu X, Ren X, Zhang Z. Deep single-cell RNA sequencing data of individual T cells from treatment-naïve colorectal cancer patients. Sci Data 2019;6:131. [PMID: 31341169 DOI: 10.1038/s41597-019-0131-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
453 Fink C, Smith M, Gaudet JM, Makela A, Foster PJ, Dekaban GA. Fluorine-19 Cellular MRI Detection of In Vivo Dendritic Cell Migration and Subsequent Induction of Tumor Antigen-Specific Immunotherapeutic Response. Mol Imaging Biol 2020;22:549-61. [DOI: 10.1007/s11307-019-01393-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
454 Zhang Y, Chen B. Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis. Dis Markers 2019;2019:2513026. [PMID: 31354887 DOI: 10.1155/2019/2513026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
455 Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci 2019;20:E2810. [PMID: 31181772 DOI: 10.3390/ijms20112810] [Cited by in Crossref: 29] [Cited by in F6Publishing: 40] [Article Influence: 9.7] [Reference Citation Analysis]
456 Luo L, Lv M, Zhuang X, Zhang Q, Qiao T. Irradiation increases the immunogenicity of lung cancer cells and irradiation-based tumor cell vaccine elicits tumor-specific T cell responses in vivo. Onco Targets Ther 2019;12:3805-15. [PMID: 31190880 DOI: 10.2147/OTT.S197516] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
457 Carreras J, Lopez-Guillermo A, Kikuti YY, Itoh J, Masashi M, Ikoma H, Tomita S, Hiraiwa S, Hamoudi R, Rosenwald A, Leich E, Martinez A, Roncador G, Villamor N, Colomo L, Perez P, Tsuji NM, Campo E, Nakamura N. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. J Clin Exp Hematop 2019;59:1-16. [PMID: 30918139 DOI: 10.3960/jslrt.19003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
458 Mizukoshi E, Kaneko S. Telomerase-Targeted Cancer Immunotherapy. Int J Mol Sci 2019;20:E1823. [PMID: 31013796 DOI: 10.3390/ijms20081823] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
459 Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat 2019;43:10-28. [PMID: 31005030 DOI: 10.1016/j.drup.2019.04.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
460 Todryk S, Jozwik A, de Havilland J, Hester J. Emerging Cellular Therapies: T Cells and Beyond. Cells 2019;8:E284. [PMID: 30917514 DOI: 10.3390/cells8030284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
461 Filipić B, Stojić-vukanić Z. Active immunotherapy of cancer: An overview of therapeutic vaccines. Arhiv za farmaciju 2019;69:490-506. [DOI: 10.5937/arhfarm1906490f] [Reference Citation Analysis]
462 [DOI: 10.1101/2020.07.15.204172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]